<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Mol Immunol</journal-id><journal-id journal-id-type="pmc-domain-id">3815</journal-id><journal-id journal-id-type="pmc-domain">pheelsevier</journal-id><journal-title-group><journal-title>Molecular Immunology</journal-title></journal-title-group><issn pub-type="ppub">0161-5890</issn><issn pub-type="epub">1872-9142</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Elsevier - PMC COVID-19 Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10009586</article-id><article-id pub-id-type="pmcid-ver">PMC10009586.1</article-id><article-id pub-id-type="pmcaid">10009586</article-id><article-id pub-id-type="pmcaiid">10009586</article-id><article-id pub-id-type="pmid">36921486</article-id><article-id pub-id-type="doi">10.1016/j.molimm.2023.03.009</article-id><article-id pub-id-type="pii">S0161-5890(23)00052-4</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Mechanistic insight into the protective and pathogenic immune-responses against SARS-CoV-2</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0005"><name name-style="western"><surname>Purbey</surname><given-names initials="PK">Prabhat K.</given-names></name><xref rid="aff0005" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au0010"><name name-style="western"><surname>Roy</surname><given-names initials="K">Koushik</given-names></name><xref rid="aff0010" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au0015"><name name-style="western"><surname>Gupta</surname><given-names initials="S">Sandeep</given-names></name><xref rid="aff0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0020"><name name-style="western"><surname>Paul</surname><given-names initials="MK">Manash K.</given-names></name><xref rid="aff0020" ref-type="aff">d</xref><xref rid="aff0025" ref-type="aff">e</xref><xref rid="cor2" ref-type="corresp">&#8270;&#8270;</xref></contrib><aff id="aff0005"><label>a</label>Department of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA</aff><aff id="aff0010"><label>b</label>Microbiology and Immunology, Department of Pathology, School of Medicine, University of Utah, Salt Lake City, UT 84112, USA</aff><aff id="aff0015"><label>c</label>Department of Neurobiology, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA</aff><aff id="aff0020"><label>d</label>Department of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA</aff><aff id="aff0025"><label>e</label>Department of Microbiology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding author.</corresp><corresp id="cor2"><label>&#8270;&#8270;</label>Corresponding author at: Department of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California Los Angeles (UCLA), Los Angeles, CA 90095, USA.</corresp><fn id="fn1"><label>1</label><p id="ntp0005">Equal contribution</p></fn></author-notes><pub-date pub-type="ppub"><month>4</month><year>2023</year></pub-date><pub-date pub-type="epub"><day>10</day><month>3</month><year>2023</year></pub-date><volume>156</volume><issue-id pub-id-type="pmc-issue-id">431088</issue-id><fpage>111</fpage><lpage>126</lpage><history><date date-type="received"><day>30</day><month>5</month><year>2022</year></date><date date-type="rev-recd"><day>20</day><month>2</month><year>2023</year></date><date date-type="accepted"><day>7</day><month>3</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>10</day><month>03</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>13</day><month>03</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-26 10:25:39.780"><day>26</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 Published by Elsevier Ltd.</copyright-statement><copyright-year>2023</copyright-year><copyright-holder/><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="ab0010"><p>COVID-19 is a severe respiratory illness that has emerged as a devasting health problem worldwide. The disease outcome is heterogeneous, which is most likely dependent on the immunity of an individual. Asymptomatic and mildly/moderate symptomatic (non-severe) patients likely develop an effective early immune response and clear the virus. However, severe symptoms dominate due to a failure in the generation of an effective and specific early immune response against SARS-CoV-2. Moreover, a late surge in pathogenic inflammation involves dysregulated innate and adaptive immune responses leading to local and systemic tissue damage and the emergence of severe disease symptoms. In this review, we describe the potential mechanisms of protective and pathogenic immune responses in &#8220;mild/moderate&#8221; and &#8220;severe&#8221; symptomatic SARS-CoV-2 infected people, respectively, and discuss the immune components that are currently targeted for therapeutic intervention.</p></abstract><kwd-group id="keys0005"><title>Keywords</title><kwd>SARS-CoV-2</kwd><kwd>Innate immunity</kwd><kwd>Adaptive immunity</kwd><kwd>Protective and pathogenic immune response</kwd><kwd>Mild/ moderate</kwd><kwd>Severe</kwd><kwd>COVID-19</kwd><kwd>Therapeutics</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec0005"><label>1</label><title>Introduction</title><p id="p0030">The Coronavirus disease 2019 (COVID-19) has emerged in December 2019 in Wuhan City of China and is caused by a novel coronavirus, named as &#8220;Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) based on its genetic similarity with the previously emerged SARS-CoV. Previously, the SARS-CoV and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) have created epidemics in 2002 and 2012, respectively (<xref rid="bib178" ref-type="bibr">Xu et al., 2020b</xref>). SARS-CoV-2 causes severe acute respiratory syndrome and other clinical symptoms that are similar to the previous coronaviruses. However, due to its higher rate of human-to-human transmission, SARS-CoV-2 has created a devastating pandemic with a much higher toll on human lives and the economy (<xref rid="bib69" ref-type="bibr">Hirano and Murakami, 2020</xref>). As per the World Health Organization (WHO), the number of confirmed cases and deaths worldwide are 756,291,327 and 6,841,640, respectively, and the impact is still pressing with evolving subvariants and COVID-19 breakouts (<xref rid="bib153" ref-type="bibr">Smith et al., 2022</xref>). The vital clinical symptoms of COVID-19 include fever, dry cough, fatigue, sputum production, dyspnea, myalgia, sore throat, and chills; while a small percentage of patient exhibits gastrointestinal infection-related symptoms (<xref rid="bib90" ref-type="bibr">Li et al., 2020</xref>). There is a substantial prevalence of clinically asymptomatic infections, whereas a varying level of symptoms is associated with symptomatic COVID-19. Based on the disease severity, COVID-19 patients can be classified roughly into two categories, non-severe (asymptomatic and mild/ moderate) and severe. The mild/ moderate category includes patients with less severe clinical symptoms, including low-grade fever, cough, discomfort with no/ mild evidence of pneumonia, and not requiring ICU admission (<xref rid="bib180" ref-type="bibr">Xu et al., 2020d</xref>, <xref rid="bib182" ref-type="bibr">Yang et al., 2020</xref>, <xref rid="bib188" ref-type="bibr">Zhao et al., 2020b</xref>, <xref rid="bib192" ref-type="bibr">Zhu et al., 2020</xref>). The severe category includes patients with high viral load, severe pneumonia, acute respiratory distress syndrome (ARDS), other systemic symptoms such as organ failure, and may or may not need an ICU admission (<xref rid="bib189" ref-type="bibr">Zhao et al., 2020c</xref>). Asymptomatic, mild/ moderate, and severe patients are all associated with viral shedding and human-to-human transmission. Most of the SARS-CoV-2 infected people (&#8764; 80%) are non-severe that get recovered on their own or with conventional medications (<xref rid="bib98" ref-type="bibr">Ma et al., 2021</xref>). Severe symptoms are observed mostly in older people and patients with pre-existing medical conditions, including cardiovascular disease, chronic respiratory diseases, and diabetes. Approximately 15% of patients exhibited symptoms of progressive pneumonia, and approximately 5% of patients develop ARDS and multiple-organ failure (<xref rid="bib25" ref-type="bibr">Cao, 2020</xref>, <xref rid="bib179" ref-type="bibr">Xu et al., 2020c</xref>). Some COVID-19 patients also exhibit persistent clinical manifestations for several months beyond the onset of recovery, a condition recognized as the "long COVID" or post-acute sequelae SARS-CoV-2 infection (PASC) (<xref rid="bib40" ref-type="bibr">Davis et al., 2023</xref>). These observations raise an important question; why do some individuals develop severe disease whereas many others do not?</p><p id="p0035">Frequent battles between viruses and their hosts lead to the evolution of both hosts and virus species in a manner that can benefit their survival (<xref rid="bib48" ref-type="bibr">Enard et al., 2016</xref>). Although viral pandemics could activate the process of natural selection and species evolution, they often cause mass casualty and economic loss. Coronaviruses have co-existed with animals, possibly for millions of years (<xref rid="bib172" ref-type="bibr">Wertheim et al., 2013</xref>), and diverse species of bats and birds act as natural hosts. When viruses, including coronaviruses, undergo cross-species transmission, they cause more severe pathogenesis (<xref rid="bib193" ref-type="bibr">Ziegler et al., 2020</xref>). The chronology of the SARS-CoV-2 evolution is discussed in detail in many reviews (<xref rid="bib79" ref-type="bibr">Jin et al., 2020</xref>, <xref rid="bib132" ref-type="bibr">Rothan and Byrareddy, 2020</xref>). The immune system, of the alternative host, is a vital defense mechanism to fight against viruses. The jaw vertebrates have evolved a specialized adaptive immune system in addition to the more ancient innate immune system to combat such infections. The innate and adaptive immune system of the host co-ordinates with each other to orchestrate a cascade of immune reactions leading to the effective elimination of the pathogen and generation of immune memory (<xref rid="bib36" ref-type="bibr">Cooper and Alder, 2006</xref>). The primary strain, which started in China&#8217;s Wuhan city, underwent significant evolution of its genome (via random mutations), leading to mutants or genetic variants. The development of new SARS-CoV-2 strains and subvariants has exacerbated the problem. As per the CDC, the strains that became concerning includes, B.1.1.7 [Alpha (&#945;) &#8211; 2020, United Kingdom], B.1.351 [Beta (&#946;) - 2020; South Africa], P.1 [Gamma (&#947;) - 2020; Brazil], B.1.617.2 [Delta (&#948;) - 2020; India], and B.1.1.529 [Omicron (&#927;) - 2021; South Africa. The other important variants are B.1.427/B.1.429 [Epsilon (&#949;) &#8211; 2020; USA)], P.2 [zeta (&#950;) &#8211; 2020; Brazil], B.1.525 (Eta (&#951;) - 2020; Multiple countries), P.3 [Theta (&#952;) &#8211; 2021; Phillipines], B.1.526 [Iota (&#953;) &#8211; 2020; USA], B.1.617.1 [Kappa (&#954;) &#8211; 2020; India], C.37 [Lambda (&#955;) &#8211; 2022, Peru) (<xref rid="bib5" ref-type="bibr">Aleem et al., 2022</xref>). As of January 2023, Omicron subvariants accounts for &gt;&#160;98% of variant of concern (VOC), as per SARS-CoV-2 genomic sequencing data submitted to &#8220;Global Initiative on Sharing Avian Influenza Data (GISAID, gisaid.org)&#8221; during February 2022 through January 2023. The current concerning omicron subvariants are XBB.1.5, CH.1.1, and BF.7 and exhibits strong immune evasion (<xref rid="bib23" ref-type="bibr">Callaway, 2023</xref>). Numerous mutations, particularly in the S protein, are present in the novel strains, augmenting the virus-angiotensin-converting enzyme-2 (ACE-2) binding efficiency, resulting in high infections, mortality rates, and new waves of illness worldwide (<xref rid="bib100" ref-type="bibr">Malik et al., 2022</xref>).</p><p id="p0040">SARS-CoV-2 induces acute inflammation and dysregulation of innate and adaptive immune systems of the human host, leading to local and systemic tissue damage in severe COVID-19 patients. The symptoms are either absent or diminished in asymptomatic and mild/moderate disease conditions (<xref rid="bib74" ref-type="bibr">Huang et al., 2020</xref>, <xref rid="bib180" ref-type="bibr">Xu et al., 2020d</xref>). A comprehensive understanding of the roles of innate and adaptive immune responses during the &#8220;mild/ moderate&#8221; and &#8220;severe&#8221; disease conditions is lacking (<xref rid="bib74" ref-type="bibr">Huang et al., 2020</xref>). Therefore, understanding the host-pathogen interactions, immune-mediated clearance, and immuno-pathogenesis of SARS-CoV-2 infection can help hypothesize, design experiments, and strategize effective solutions to combat the COVID-19 pandemic or similar pandemics in the future. This review explores the potential immunological events in the human host during &#8220;effective clearance&#8221; as well as during the &#8220;establishment of severe clinical symptoms&#8221; of SARS-CoV-2 infection. We also summarize potential therapeutic strategies targeting immune components to control the severity of COVID-19.</p></sec><sec id="sec0010"><label>2</label><title>The infection process of SARS-CoV-2</title><p id="p0045">COVID-19 is highly contagious, and human-to-human transmission occurs when a patient's respiratory droplets get deposited in the nasal, oral, and conjunctival mucosa of an uninfected person via droplets, aerosol, and physical contact (<xref rid="bib12" ref-type="bibr">Banerjee et al., 2021</xref>; <xref rid="bib141" ref-type="bibr">Sanyal and K. Paul, 2021</xref>). SARS-CoV-2 mainly targets the respiratory tracts, but other organs like the gut, heart, blood vessels, kidney, brain, and the central nervous system are also affected. Epithelial cell lining of the nasal passage, upper respiratory tract, and lungs (especially the goblet, ciliated, and type II alveolar cells) are the primary infection targets due to the higher expression of SARS-CoV-2-interacting host proteins (<xref rid="bib133" ref-type="bibr">Roy et al., 2021</xref>, <xref rid="bib138" ref-type="bibr">Salian et al., 2021</xref>, <xref rid="bib161" ref-type="bibr">Sungnak et al., 2020</xref>, <xref rid="bib177" ref-type="bibr">Xu et al., 2020a</xref>). Other cell types like endothelial cells, fibroblast, myeloid cells, lymphocytes, and epithelial cells in many organs are also potential infection targets. (www.covid19cellatlas.org.) (<xref rid="bib4" ref-type="bibr">Akhmerov and Marban, 2020</xref>, <xref rid="bib10" ref-type="bibr">Asadi-Pooya and Simani, 2020</xref>, <xref rid="bib33" ref-type="bibr">Cheng et al., 2020</xref>, <xref rid="bib67" ref-type="bibr">Henry and Lippi, 2020</xref>, <xref rid="bib97" ref-type="bibr">Lukassen et al., 2020</xref>, <xref rid="bib112" ref-type="bibr">Muus et al., 2020</xref>, <xref rid="bib171" ref-type="bibr">Wang et al., 2020</xref>). Further spread of the coronavirus from the lung to other organs may involve circulating infected immune cells (e.g., lymphocytes, monocytes, macrophages) (<xref rid="bib61" ref-type="bibr">Gu et al., 2005</xref>, <xref rid="bib112" ref-type="bibr">Muus et al., 2020</xref>, <xref rid="bib133" ref-type="bibr">Roy et al., 2021</xref>). Infection and associated immunopathology of other organs need further investigation. The target-cell entry mechanisms of SARS-CoV-2 is critical in host-immune monitoring and is briefly discussed in the following section.</p><p id="p0050">SARS-CoV-2 is a positive-sense single-stranded enveloped RNA (+ssRNA) virus. The genome is annotated to encode as many as 14 open reading frames (ORFs) and encodes proteases, RNA-dependent RNA polymerase, and several structural proteins (
<xref rid="fig0005" ref-type="fig">Fig. 1</xref>). The essential SARS-CoV-2 structural proteins are the Spike (S) glycoprotein, Envelope (E) protein, Membrane (M) glycoprotein, and Nucleocapsid (N) protein. The SARS-CoV-2&#8217;s S protein attaches to the entry receptor angiotensin-converting enzyme 2 (ACE2) on the host cell surface, followed by its proteolytic activation. Cell surface Transmembrane protease serine 2 protein (TMPRSS2) and lysosomal cathepsin protease-mediated proteolytic cleavage of viral S protein is important for viral endocytosis and infection (<xref rid="bib70" ref-type="bibr">Hoffmann et al., 2020</xref>). The internalized SARS-CoV-2 undergoes the viral replication cycle (<xref rid="fig0005" ref-type="fig">Fig. 1</xref>) (<xref rid="bib90" ref-type="bibr">Li et al., 2020</xref>, <xref rid="bib190" ref-type="bibr">Zhou et al., 2020a</xref>).<fig id="fig0005" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>The infection cycle of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). 1. The key to the coronavirus infection is its binding to the receptor angiotensin-converting enzyme 2 (ACE2) on the host cells. SARS-CoV-2 spike protein (S) is primed by the transmembrane protease, serine 2 (TMPRSS2), leading to the interaction with the membrane-bound form of ACE2. This interaction is a critical step in viral internalization. The routes employed by SARS-CoV-2 include endocytosis and membrane fusion. 2. After the viral entry into the host cell, followed by peeling off the viral envelope, the viral genomic RNA is released in the cytoplasm. 3. The virus hijacks the host machinery to transcribe, replicate, and translate. ORF1a and ORF1b of the genomic RNA are translated into nonstructural proteins. Some nonstructural proteins form a replication/transcription complex (RNA-dependent RNA polymerase, RdRp), which use the (+) strand genomic RNA as a template. The (+) strand genomic RNA produced through the replication process becomes the genome of the new virus particle. SARS-CoV-2 virus sub genomic RNA encodes four major structural proteins: The S protein, the nucleocapsid (N) protein; the membrane (M) protein; and the envelope (E) protein. 4. The synthesized proteins are trafficked from the endoplasmic reticulum (ER) to the Golgi. Furthermore, the nucleocapsid protein is combined with the (+) strand genomic RNA. 5. The protein and RNA assemble into the complete virus particle in the Endoplasmic Reticulum-Golgi apparatus compartment. 6. The viral particles are finally excreted to the extracellular region for new infections.</p></caption><alt-text id="at0005">Fig. 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1_lrg.jpg"/></fig></p></sec><sec id="sec0015"><label>3</label><title>Immune response to SARS-CoV-2</title><p id="p0055">The anti-SARS-CoV-2 immune response is most likely initiated in the infected respiratory cells by the activation of various immune components to ameliorate disease progression. COVID-19 disease severity seems to largely depend on the hosts&#8217; immunity against SARS-CoV-2. Asymptomatic and mild/ moderate symptomatic patients, who likely develop a compelling early immune response, exhibit successful viral clearance. While patients with severe symptoms (especially the elderly and those with pre-existing health conditions) generate a dysfunctional early immune response against SARS-CoV-2 leading to life-threatening complications (<xref rid="bib74" ref-type="bibr">Huang et al., 2020</xref>, <xref rid="bib180" ref-type="bibr">Xu et al., 2020d</xref>). Inadequate early immune response allows immune evasion, viral propagation, the spread of infection and subsequently cell death, and the release of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). These signals trigger late uncontrolled inflammation (local and then systemic) and substantial tissue damage.</p><p id="p0060">The immune system of mammals has been sub-grouped into innate and adaptive immune systems. The innate and adaptive systems are different in terms of their response time, specificity, and type of immune cells involved, but both the systems coordinate with each other in generating effective anti-viral immunity. In the subsequent sections, we will discuss innate and adaptive immune responses to SARS-CoV-2 infection.</p><sec id="sec0020"><label>3.1</label><title>Innate Immune Response to SARS-CoV-2</title><p id="p0065">Innate defense against SARS-CoV-2 initiates at the level of physical barriers and mucociliary clearance in the upper respiratory tract. As the SARS-CoV-2 breaches the physical barriers and infects its target cells, a coordinated host innate immune response is rapidly mounted upon the recognition of viral PAMPs (<xref rid="bib136" ref-type="bibr">Saksena et al., 2023</xref>). Although the innate immune response is considered as non-specific, a limited specificity is generated by the engagement of the types of receptors and sensors present at the cell surface, endosome, and cytoplasm for the detection of PAMPs (<xref rid="bib126" ref-type="bibr">Reikine et al., 2014</xref>). Besides receptor and sensors-mediated innate immune signaling, the host&#8217;s complement systems also target the virus and virus-infected cells to aid the innate-immune cell response (discussed in <xref rid="sec0050" ref-type="sec">Section 3.3</xref>). The generation of an effective innate immune response is essential to facilitate the development of a more specific adaptive immune response that involves lymphocytes (discussed in <xref rid="sec0055" ref-type="sec">Section 4</xref>). SARS-CoV-2 infection-associated outcome can be attributed to an appropriate host innate immune response. This review features type-I interferon (IFN-I) and pro-inflammatory cytokines, innate immune cells, and complement activation.</p><sec id="sec0025"><label>3.1.1</label><title>IFN-I and pro-inflammatory cytokines in SARS-CoV-2 infected patients</title><p id="p0070">To successfully combat and generate immune memory, the host&#8217;s cells generate an early innate immune response that includes the production of antiviral IFN-I and proinflammatory cytokines soon upon viral detection (<xref rid="bib82" ref-type="bibr">Kikkert, 2020</xref>). Based on preclinical and clinical data from coronavirus epidemics, it is apparent that a large proportion of the human population can generate such an early innate immune response despite virus-mediated subverting mechanisms (discussed in <xref rid="sec0025" ref-type="sec">Section 3.1.1</xref>.). However, a significant proportion of patients fail to do so, which leads to uncontrolled immune cell-mediated inflammation and severe symptoms (discussed in <xref rid="sec0030" ref-type="sec">Section 3.1.2</xref>.). Therefore, depending on the host&#8217;s immunity, this innate immune response to SARS-CoV-2 could be protective or detrimental, which is primarily determined by the timing of its onset. (<xref rid="bib82" ref-type="bibr">Kikkert, 2020</xref>). There are limited reports about the nature and composition of early IFN-I and proinflammatory cytokines production in patients who have recovered from a SARS-CoV-2 infection. At the late stage, a decreased level of IFN-I (IFN&#945;, Interferon-stimulated genes (ISGs)) and IFN-II (IFN-&#947;) along with an elevated level of many pro-inflammatory cytokines and chemokines (such as IL-6, Tumor, necrosis factor (TNF), IL-8, IL-1&#946;, IL-2, IL-8, IL-17, G-CSF, GM-CSF, CXCL10, MCP1, and CCL3) has been documented in the severe COVID-19 patients as compared to the non-severe COVID-19 patients (<xref rid="bib25" ref-type="bibr">Cao, 2020</xref>, <xref rid="bib99" ref-type="bibr">Magro et al., 2020</xref>, <xref rid="bib122" ref-type="bibr">Prompetchara et al., 2020</xref>, <xref rid="bib153" ref-type="bibr">Smith et al., 2022</xref>). The elevated cytokines level is characterized as a cytokine storm, which seems to be significantly contributed by the innate immune cells and to some extent by the adaptive immune cells as well.</p></sec><sec id="sec0030"><label>3.1.2</label><title>Effective early innate immune response against SARS-CoV-2</title><p id="p0075">A study of 10 mild/ moderate symptomatic COVID-19 patients has indicated generation of an early pro-inflammatory (TNF&#945;, IL6, IL10, and IFN-&#947;) response that subsided as the infection resolved (<xref rid="bib43" ref-type="bibr">Diao et al., 2020a</xref>). However, a shortcoming with this study is that IFN-I and many other inflammatory cytokines (IL-1&#946;, MCP-1, CCL2, CXCL10, etc.) were not monitored. Smith et al. employed multi-IFN subtypes digital ELISA to demonstrate poor activation and modulation of type I interferon immunity in COVID-19 patients who were critically sick, as compared to uninfected and moderate group (<xref rid="bib153" ref-type="bibr">Smith et al., 2022</xref>). A recent report with 100 mild and sever patients in Tehran suggests that the reduced levels of IFN-I signaling and higher autoantibody against IFN-&#945; may be associated with the severity of the COVID symptoms in patients (<xref rid="bib154" ref-type="bibr">Soltani-Zangbar et al., 2022</xref>). Although, higher autoantibody against IFN-&#945; may potentially dampen the antiviral role of IFN-I and making life threatening condition of the patient (<xref rid="bib15" ref-type="bibr">Bastard et al., 2020</xref>), a detailed time-course, (especially at early time points) monitoring of IFN-I and important cytokines would be needed to stratify patients for better therapeutic intervention.</p><p id="p0080">IFN-I acts in a paracrine manner on many cell types (e.g., virally infected cells, alveolar macrophages, neutrophils, dendritic cells, etc.) expressing interferon receptors &#8220;IFNAR&#8221;. IFN-I binds to IFNAR and activates the JAK-STAT pathway, which induces a battery of Interferon-stimulated genes (ISGs) with diverse antiviral and immune-modulating functions. SARS-CoV-2 being a (+)ssRNA virus, may induce IFN-I and other proinflammatory cytokines in the infected cells and surrounding innate immune cells similar to other RNA viruses (<xref rid="bib70" ref-type="bibr">Hoffmann et al., 2020</xref>, <xref rid="bib122" ref-type="bibr">Prompetchara et al., 2020</xref>, <xref rid="bib190" ref-type="bibr">Zhou et al., 2020a</xref>). The generation of anti-viral early innate immune response including IFN-I by RNA virus should ideally engage sensors in endosomes (Toll-like receptors &#8220;TLR-3&#8221; and &#8220;TLR-7&#8221;)], cytoplasm (Retinoic acid-inducible gene-I &#8220;RIG-I&#8221;, Melanoma differentiation-associated protein 5 &#8220;MDA-5&#8221;)] and potentially other sensors (<xref rid="bib162" ref-type="bibr">Takeuchi and Akira, 2009</xref>) (
<xref rid="fig0010" ref-type="fig">Fig. 2</xref>). A couple of SARS-CoV and MERS-CoV infections studies in the mouse model, have noted a difference in sensing of coronavirus derived RNA in lung epithelial cells (key target cells) and other innate immune cells (<xref rid="bib30" ref-type="bibr">Channappanavar et al., 2019b</xref>). For example, to sense MERS-CoV derived RNA, innate immune cells such as macrophages can engage both RIG-I/ MDA5 and TLR7 pathways, whereas epithelial cells engage the TLR7 pathway only. Recent studies involving modeling of early SARS-CoV-2 infection using primary lung epithelial cells, epithelial cell lines (Calu-3) and induced pluripotent stem cell-derived airway epithelium cells, suggest that SARS-Cov-2 infection triggers interferon response via MDA5, LGP2 and NOD1 sensor proteins but not the TLR3. Contradictory results about the involvement of RIGI is also published (<xref rid="bib166" ref-type="bibr">Thorne et al., 2021</xref>, <xref rid="bib183" ref-type="bibr">Yin et al., 2021</xref>). IRF3, IRF5 and NF-kB/p65 transcription factors seems to induce the interferon production (<xref rid="bib183" ref-type="bibr">Yin et al., 2021</xref>). The interferon and cytokine produced by infected cells supernatant can strongly activate macrophages. They argue that inflammatory state of the lungs&#8217; macrophages and epithelial cells may determine the disease severity as SARS-CoV-2 infection drives higher inflammatory response when macrophages and epithelial cells are pre-exposed to inflammatory signals in vitro (<xref rid="bib166" ref-type="bibr">Thorne et al., 2021</xref>). However, it remains to be determined how this recent zoonotic virus adapted to evade the innate immune response of a new host (humans) and the mechanisms that render it insensitive to the IFN signaling induced by the infection. Questions that remains unanswered are, first, whether severe patients have defects in eliciting IFN-I response, second, which components of sensing mechanism contributes to this defect, associated genetic mutations (e.g. TLR3, TLR7) and finally, whether young adults mount stronger IFN-I response as compared to older people? Characterizing the mechanistic differences of these early innate immune response in young adults and older people may help devise strategies to save severe COVID-19 patients.<fig id="fig0010" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Mechanistic insight into the immune-responses against SARS-CoV-2 during non-severe (asymptomatic/ mild/ moderate) and severe condition. SARS-CoV-2 infects lung epithelial cells as the primary target. Intracellular sensing of viral RNAs by cytosolic RIG-I/ MDA5/ and membrane-bound TLR-3 and TLR-9 can lead to antiviral signaling. RIG-I/MDA5 acts through MAVS, and TLR-3 and TLR-7 act through TRIF and MYD88, respectively, to activate IRF3 and NF-kB to produce host defense molecules such as IFNs, proinflammatory cytokines, and chemokines. The secreted IFNs induce the expression of interferon-stimulated genes (ISGs) that play crucial roles in inhibiting the viral propagation and activation of innate and adaptive immune responses. Moreover, secreted cytokines, viral PAMPs, and DAMPs can activate innate immune cells and cause local inflammation. Left side (immune response in severe condition): In an inadequate early immune response, uncontrolled viral propagation and aberrant host cell death can release higher amounts of DAMPs and PAMPs. Elevated levels of DAMPs and PAMPs can initiate and perpetuate resident immune cell activation and promote infiltration of innate (DC, MQ, 2 AM cells) and adaptive (CD4&#8201;+ T cells) immune cells to produce a higher amount of pro-inflammatory cytokines, chemokines and IFNs. The released chemokines and cytokines can recruit more immune cells to the site of infection by blood vessel leakage and chemotaxis and further perpetuate the production of cytokines to aggravate the inflammation further. This elevated positive pro-inflammatory feedback loop is characterized as a cytokine storm (IL-6, IP-10, MIP1&#945;, MIP1&#946; and MCP1, TNF, IL1-&#946;, etc.) that can lead to the damage of infected and distant organs. Elevated cytokines levels and excess cell death-released antigens may cause continuous, unrestricted stimulation of memory cells. Stimuli-activated memory B cells can trigger polyclonal antibody production (likely non-neutralizing) that may further enhance SARS-CoV-2 infection through antibody-dependent enhancement (ADE) and contribute to multi-organ damage. Higher cytokine (likely IL-6) levels may lead to inhibition of T cell activation and lymphopoiesis. Right Side (immune response in non-severe condition): The optimal local inflammation attracts dendritic cells (DCs), macrophages (M&#632;) and virus-specific lymphocytes to the site of infection. Antigen-presenting cells (DC, M&#632;, B cell) can present viral antigen to CD8&#8201;+&#8201;T cells and CD4&#8201;+&#8201;T cells. Activated CD8&#8201;+&#8201;T cells can eliminate the infected cells by secreting granzyme B, perforin, and IFN-&#947;. Activated CD4&#8201;+&#8201;T cells can produce IFN-&#947;, proinflammatory cytokines, and trigger differentiation of viral antigen-specific B cells. B cells differentiated into plasma cells and memory B cells are specific to viral antigens. The plasma cells produce optimal antibodies (higher titer of neutralizing antibodies), which can lead to the clearance of the virus. These timely, regulated, and coordinated immune responses effectively clear the virus without causing any damage to the organ (lung) and provide long term immunity.</p></caption><alt-text id="at0010">Fig. 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2_lrg.jpg"/></fig></p></sec><sec id="sec0035"><label>3.1.3</label><title>SARS-CoV-2 may limit the host&#8217;s early IFN-I response</title><p id="p0085">SARS-CoV-2, like other viruses, has evolved mechanisms to impair the early anti-viral IFN-I response to evade the host&#8217;s immunity by implementing multiple potential mechanisms. SARS-CoV-2 may interfere with IFN-I response by the following mechanisms. First, SARS-CoV-2 may limit the generation of the viral-PAMPs (RNA) by endoribonuclease activity of non-structural protein &#8220;NSP15&#8221; (<xref rid="bib64" ref-type="bibr">Hackbart et al., 2020</xref>). Second, the impaired ubiquitination-mediated activation of RNA-sensor &#8220;RIG-I&#8221; by nucleocapsid (N) protein might cause a shift in the RNA-sensing (<xref rid="bib73" ref-type="bibr">Hu et al., 2017</xref>). Third, ORF of SARS-CoV-2 may limit IFN-I production, similar to SARS-CoV. SARS-CoV encoded proteins, such as ORF6, and ORF3b that may dampen IFN-I effect by acting on signaling up/ downstream of the IFNAR receptor (<xref rid="bib95" ref-type="bibr">Lokugamage et al., 2020</xref>). Fourth, delayed exposure of PAMPS to induce the IFN-I signaling. Indeed, recent findings suggest that ORF6 of SARS-CoV-2 inhibit the interferon response by directly interacting with proteins involved in cytokine signaling. For example, ORF6 is shown to interact with STAT1, an important mediator of cytokine signaling, to prevent STAT1 localization in the nucleus, thereby preventing the interferon response (<xref rid="bib109" ref-type="bibr">Miyamoto et al., 2022</xref>), or by directly interacting with the cellular trafficking protein-Rae6 to block the export of mRNAs encoding IRF1 (interferon regulatory factor 1) and the sensor protein- RIG1 (<xref rid="bib63" ref-type="bibr">Haagmans et al., 2022</xref>). Delayed mounting of IFN-I response by infected cells is evident by several studies (<xref rid="bib166" ref-type="bibr">Thorne et al., 2021</xref>). Therefore, possibly, an early IFN-I therapy may ameliorate SARS-CoV-2 infection (<xref rid="bib95" ref-type="bibr">Lokugamage et al., 2020</xref>). The model of early IFN-1 theory is further evaluated by screening of all 12 IFN-1 subtypes against SARS-CoV-2 infection which identified a group of effective IFN subtypes that can be therapeutically useful to treat acute infection upon SARS-Cov-2 exposure (<xref rid="bib143" ref-type="bibr">Schuhenn et al., 2022</xref>).</p></sec><sec id="sec0040"><label>3.1.4</label><title>Pathogenic delayed pro-inflammatory cytokines production in severe COVID-19 patients</title><p id="p0090">Approximately 15&#8211;20% of COVID-19 patients with severe symptoms are unable to mount an early efficient innate immune response, which leads to uncontrolled viral propagation, aberrant cell death and release of virus-associated PAMPs, and cellular DAMPs (including nuclear DNAs). Aberrant cell deaths may induce acute lung injury (ALI) and danger signal-triggered immune responses, inflammation, and associated immunopathology in COVID-19 patients via multiple mechanisms (discussed in <xref rid="sec0020" ref-type="sec">Section 3.1</xref>) (<xref rid="bib130" ref-type="bibr">Rock and Kono, 2008</xref>). Briefly, the release of PAMPs and DAMPs from infected lung epithelium can engage many sensors/ receptors in the resident and infiltrated innate immune cells, leading to massive production of pro-inflammatory cytokines that may have various effects at the local and systemic level (<xref rid="fig0010" ref-type="fig">Fig. 2</xref>). The surge in cytokines and chemokines can stimulate the infiltration of neutrophils, monocytes-macrophages, dendritic cells, T cells, B cells, antibodies, and activated complement proteins in the lung parenchyma. The infiltrated immune cells can ultimately aggravate the patient's condition by contributing to the overproduction of a variety of cytokines (cytokine storm), and immune-mediated tissue and vasculature damage. Systemically, some of the cytokines may act on the hematopoietic stem/ progenitor cells to trigger an increased production of neutrophils and other myeloid cells along with a concomitant decrease in lymphocyte production (leading to lymphopenia). Many of the cytokines can also exert a pathogenic effect on distant organs such as blood vessels, hearts, liver, kidney, and intestine (<xref rid="bib184" ref-type="bibr">Zaim et al., 2020</xref>). Experimentally, similar phenomena were also reported in a mouse model of the MERS-CoV study (<xref rid="bib29" ref-type="bibr">Channappanavar et al., 2019a</xref>).
<xref rid="fig0015" ref-type="fig">Fig. 3</xref> describes the kinetics of clinical courses of major symptoms and cytokine response in mild/ moderate and severe COVID-19 patients. At this stage of the disease, it will be essential to identify each of the detrimental immune components (cell types and cytokines) for better management of COVID-19.<fig id="fig0015" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Proposed kinetics of immune responses and their relationship with the severity of the SARS-CoV-2 infection in non-severe (mild/ moderate) vs. severe patients (survivors and nonsurvivors). Graphical representation of various immune responses kinetics and disease pathology in different categories of COVID-19 patients based on the current understanding. Panels A, B, and C represent the kinetics of immune responses and disease pathology in mild/ moderate, severe survivor and severe non-survivor patients, respectively. The x-axis in each panel represents the progression of the disease symptoms/ pathology with a tentative timeline in days (<xref rid="bib192" ref-type="bibr">Zhou et al., 2020</xref>). The left y-axis represents the severity of the disease for each patient category. The right y-axis represents the relative immune responses (arbitrary representation) of IFNs and proinflammatory cytokines (Red line), SARS-CoV-2 specific antibody (black line), and 3 lymphocytes count (blue line). The scales on the y-axis are relative to the maximum amplitude in non-survivors and the comparison among the panels is qualitative. The kinetics of antibody production in severe and non-severe cases are described by <xref rid="bib165" ref-type="bibr">Thevarajan et al. (2020)</xref> and <xref rid="bib190" ref-type="bibr">Zhou et al. (2020a)</xref>. The kinetics of lymphocytes number in nonsevere and severe is described by <xref rid="bib163" ref-type="bibr">Tan et al. (2020)</xref> and <xref rid="bib171" ref-type="bibr">Wang et al. (2020)</xref>. The IFNs and proinflammatory cytokine production kinetics are compiled from SARS-CoV-2, SARS-CoV and MERS-CoV infection (Zhou et al., 2020c, Oberfeld et al., 2020). Data reported in multiple articles are combined to recapitulate the kinetics of disease progression and immune response and may not accurately represent all patients (<xref rid="bib192" ref-type="bibr">Zhou et al., 2020</xref>).</p><p>tables.</p></caption><alt-text id="at0015">Fig. 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3_lrg.jpg"/></fig></p></sec></sec><sec id="sec0045"><label>3.2</label><title>Innate immune cells in SARS-CoV-2 infected people</title><p id="p0095">Limited data exists about the kinetics of innate immune cell number and activity changes in asymptomatic and mild/ moderately symptomatic SARS-CoV-2 infected people. Non-severe COVID-19 patients show a near-normal number of circulating neutrophils, NK cells, and monocytes but a drastically lower percentage of inflammatory monocytes as compared to the normal healthy control. In contrast, the severe COVID-19 patients exhibit drastically enhanced neutrophils, normal NK cells and marginally reduced monocytes in their blood as compared to the non-severe patients (<xref rid="bib27" ref-type="bibr">Chan et al., 2020</xref>, <xref rid="bib124" ref-type="bibr">Qin et al., 2020</xref>, <xref rid="bib163" ref-type="bibr">Tan et al., 2020</xref>, <xref rid="bib171" ref-type="bibr">Wang et al., 2020</xref>). Severe patients have a relatively higher percentage of inflammatory monocytes (CD14&#8201;+CD16&#8201;+) as compared to non-severe patients (<xref rid="bib191" ref-type="bibr">Zhou et al., 2020b</xref>). The time course study shows an increase of neutrophil count in non-survivor as the disease progresses, whereas surviving patients exhibit a near-normal level of neutrophil counts as they recover (<xref rid="bib27" ref-type="bibr">Chan et al., 2020</xref>, <xref rid="bib124" ref-type="bibr">Qin et al., 2020</xref>, <xref rid="bib163" ref-type="bibr">Tan et al., 2020</xref>, <xref rid="bib171" ref-type="bibr">Wang et al., 2020</xref>).</p><p id="p0100">Additionally, the patient's lungs may also exhibit increased infiltration of innate immune cells, including neutrophils, activated monocytes, dendritic cells, and mast cells (<xref rid="bib31" ref-type="bibr">Chen et al., 2020</xref>). Neutrophilia may result due to an increased myelopoiesis in response to cytokines produced during the onset of uncontrolled inflammation (<xref rid="bib124" ref-type="bibr">Qin et al., 2020</xref>). Moreover, the increased lung-specific immune-infiltration could be due to cytokine-induced increased vascular permeability and blood stasis (<xref rid="bib99" ref-type="bibr">Magro et al., 2020</xref>, <xref rid="bib169" ref-type="bibr">van de Veerdonk et al., 2020</xref>). The ALI-associated increased circulating and lungs infiltrated innate immune cells can cause a cytokine storm, which is strongly associated with the ARDS and poor outcome of COVID-19 patients.</p></sec><sec id="sec0050"><label>3.3</label><title>Complement activation in SARS-CoV-2 infected people</title><p id="p0105">Complement activation is one of the innate immune mechanisms that is involved in the clearance of viruses (<xref rid="bib3" ref-type="bibr">Agrawal et al., 2017</xref>). There are three described complement activation pathways, the classical pathway, alternative pathway, and the lectin pathway (LP). LP is initiated by binding of mannose-binding Lectins (MBL) to mannose residues on the viruses and virus-infected cell surface. MBL, in turn, binds to the SARS-CoV infected cells and the SARS-CoV spike protein resulting in the activation of the complement system (<xref rid="bib87" ref-type="bibr">Lau et al., 2005</xref>). Activation of these pathways converges on a common signaling cascade that includes the production of complement components, such as C3a and C5a, that are inflammatory mediators and initiates pathogen opsonization and lysis of the virus-infected cells (<xref rid="bib24" ref-type="bibr">Campbell and Kahwash, 2020</xref>).</p><p id="p0110">The role of activated complement is not yet reported during the development of an effective immune response leading to viral clearance in mild/ moderate symptomatic patients. Clinical studies have shown that pulmonary tissues and sera from the severe COVID-19 patients have a significantly higher level of terminal complement components (such as C5b-9, C4d, MASP2, and C5a), suggesting systemic activation of some of the complement pathways (<xref rid="bib55" ref-type="bibr">Gao et al., 2020b</xref>, <xref rid="bib99" ref-type="bibr">Magro et al., 2020</xref>). Aberrant activation of the complement system leads to immune-mediated severe symptoms in various virus infections, including coronaviruses (<xref rid="bib24" ref-type="bibr">Campbell and Kahwash, 2020</xref>, <xref rid="bib59" ref-type="bibr">Gralinski et al., 2018</xref>, <xref rid="bib160" ref-type="bibr">Sun et al., 2013</xref>). The elevated level of activated complement proteins in COVID-19 patients (both in tissues and circulation) could be due to first, the abundantly produced SARS-CoV-2&#8201;N-protein, which binds and potentiate MBL-mediated activation of MASP-2 (an essential component of lectin pathway) (<xref rid="bib55" ref-type="bibr">Gao et al., 2020b</xref>, <xref rid="bib186" ref-type="bibr">Zhang et al., 2020</xref>). Second, SARS-CoV-2 S-protein, which co-localizes with the complements, C4d, and C5b-9 in many severe patients (<xref rid="bib99" ref-type="bibr">Magro et al., 2020</xref>). Third, autoantibodies might be produced in the severe COVID-19 patients similar to SARS-CoV infection, which is known to trigger the complement activation in the autoimmune diseases (<xref rid="bib28" ref-type="bibr">Chang et al., 2021</xref>, <xref rid="bib167" ref-type="bibr">Thurman and Yapa, 2019</xref>) (discussed in <xref rid="sec0065" ref-type="sec">Section 4.2</xref>). The role of activated complement in severe lung disease is supported by a study using a complement protein mutant mice (C3<sup>-/-</sup>) model of SARS-CoV infection (<xref rid="bib59" ref-type="bibr">Gralinski et al., 2018</xref>). Activated complement contributes to the lung disease severity by various mechanisms that are described elsewhere (<xref rid="bib103" ref-type="bibr">Markiewski and Lambris, 2007</xref>, <xref rid="bib159" ref-type="bibr">Stoermer and Morrison, 2011</xref>). The complement C3a, C4a, and C5a proteins can act as anaphylatoxins with potent proinflammatory properties and can contribute to inflammatory cell recruitment and neutrophil activation in COVID19 (<xref rid="bib2" ref-type="bibr">Afzali et al., 2021</xref>, <xref rid="bib18" ref-type="bibr">Bosmann and Ward, 2012</xref>).</p><p id="p0115">Considering the role of Complement-activation in COVID-19 patients, targeted therapy has emerged as an effective treatment modality and several clinical trials have been designed to target C3, C4, and C5. The ITHACA trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04382755">NCT04382755</ext-link>) randomized C3 inhibitor AMY-101 in COVID-19 patients with severe hypoxemia. AMY-101 reduced oxygen dependence, CRP, ferritin, thrombin, and 28-day survival, but was not statistically significant (<xref rid="bib152" ref-type="bibr">Skendros et al., 2022</xref>). In the phase 2 experiment PANAMO (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04333420">NCT04333420</ext-link>), severe COVID-19 patients were administered the anti-human C5a monoclonal antibody IFX-1. Nevertheless, no statistically significant improvements in clinical endpoints were seen in severe COVID-19 patients treated with IFX-1 (<xref rid="bib42" ref-type="bibr">De Leeuw et al., 2022</xref>). Eculizumab, a monoclonal antibody targeting C5, may increase survival and minimize hypoxia in severe COVID-19 patients (<xref rid="bib8" ref-type="bibr">Annane et al., 2020</xref>).</p></sec></sec><sec id="sec0055"><label>4</label><title>Adaptive immune response to SARS-CoV-2</title><p id="p0120">The adaptive immune response is relatively delayed (usually takes 3&#8211;5 days) and mostly pathogen-specific. The lymphocytes (B and T cells) are critical components of the adaptive immune system. Co-ordinated actions of various types of lymphocytes help maintain inflammatory response and provide specific and robust protection against a pathogen. SARS-CoV-2 infection-associated outcome could be attributed to a regulated or dysregulated adaptive immune response in the host. The aspects of adaptive immune components discussed in this review include lymphocytes number, B cell and antibody function, T cell function, and memory lymphocyte generation.</p><sec id="sec0060"><label>4.1</label><title>Number of lymphocytes in SARS-CoV-2 infected people</title><p id="p0125">Non-severe COVID-19 patients show a near-normal number of circulating lymphocytes whereas severe COVID-19 patients exhibit drastically reduced number of lymphocytes in their blood, a condition termed as Lymphopenia (<xref rid="bib27" ref-type="bibr">Chan et al., 2020</xref>, <xref rid="bib124" ref-type="bibr">Qin et al., 2020</xref>, <xref rid="bib163" ref-type="bibr">Tan et al., 2020</xref>, <xref rid="bib171" ref-type="bibr">Wang et al., 2020</xref>). Analysis of lymphocyte subsets in severe cases shows a significant reduction in the number of T cells, mainly the CD4<sup>+</sup> T and NK cells, but without any significant changes in B cell number (<xref rid="bib124" ref-type="bibr">Qin et al., 2020</xref>, <xref rid="bib171" ref-type="bibr">Wang et al., 2020</xref>). The detailed time-course analysis shows that non-severe patients-maintained lymphocytes &gt;&#8201;20% and severe patients who died show a gradual reduction of lymphocytes to reach &lt;&#8201;5%. Whereas severe patients who got cured initially show reduction (&lt;10%) followed by recovery to near-normal level (15&#8211;20%) of lymphocytes (<xref rid="bib163" ref-type="bibr">Tan et al., 2020</xref>).</p><p id="p0130">The cellular mechanism of observed lymphopenia and increased neutrophil-lymphocyte-ratio in severe COVID-19 patients could be due to the following reasons and beyond. First, severe patients may be characterized by higher infiltration of the lymphocytes over neutrophil at the site of infection. Proinflammatory cytokine (such as IL-6) and chemokine (MCP1, CXCL-10) may preferentially recruit lymphocytes and monocytes at the site of infection (<xref rid="bib105" ref-type="bibr">McGonagle et al., 2020</xref>). Second, reduced lymphocyte production by skewed hematopoietic lineage specification and/ or by inhibition of lymphocyte proliferation. Inflammation can skew hematopoietic fate decision towards the myelopoiesis with a concomitant decrease in lymphopoiesis (<xref rid="bib27" ref-type="bibr">Chan et al., 2020</xref>, <xref rid="bib47" ref-type="bibr">Duggan et al., 2017</xref>, <xref rid="bib121" ref-type="bibr">Pietras, 2017</xref>, <xref rid="bib124" ref-type="bibr">Qin et al., 2020</xref>, <xref rid="bib163" ref-type="bibr">Tan et al., 2020</xref>, <xref rid="bib171" ref-type="bibr">Wang et al., 2020</xref>). Besides, severe patients are also associated with pre-existing conditions like diabetes and hypertension (<xref rid="bib182" ref-type="bibr">Yang et al., 2020</xref>). Metabolic molecules, such as elevated blood lactic acid levels may inhibit lymphocyte proliferation in severe COVID-19 cases (<xref rid="bib52" ref-type="bibr">Fischer et al., 2007</xref>, <xref rid="bib163" ref-type="bibr">Tan et al., 2020</xref>). Third, severe patients may have higher lymphocyte death. The potential mechanism of lymphocyte death could be due to direct infection of lymphocytes, cytokine storm, damage of lymphatic organ, and metabolic disorder (<xref rid="bib163" ref-type="bibr">Tan et al., 2020</xref>); (<xref rid="bib145" ref-type="bibr">Sefil et al., 2014</xref>, <xref rid="bib148" ref-type="bibr">Shen et al., 2022</xref>). Further investigation is warranted to decipher the role of COVID-associated cause of lymphopenia in severe COVID-19 cases.</p></sec><sec id="sec0065"><label>4.2</label><title>B cells and antibodies function in SARS-CoV-2 infected people</title><p id="p0135">Patients who recover from COVID-19 infection have SARS-CoV-2 binding antibodies in their sera, suggesting a role of B cells and virus-specific antibodies in providing protective immunity against SARS-CoV-2 (<xref rid="bib165" ref-type="bibr">Thevarajan et al., 2020</xref>, <xref rid="bib190" ref-type="bibr">Zhou et al., 2020a</xref>). The interaction of antigen with the na&#239;ve (or memory) B cells generates activated B cells, which then differentiate into antibody secreting cells (ASCs) with the help of T follicular helper (T<sub>FH</sub>) cells. The ASC produces antibodies that are critical for viral clearance. Detailed kinetic analysis of antibody production, ASCs, and T<sub>FH</sub> cell generation and the state of a disease condition was studied in a 47-year-old mild symptomatic patient who recovered (<xref rid="bib165" ref-type="bibr">Thevarajan et al., 2020</xref>). Viral clearance started on day 7, and symptoms were resolved on day 13. The SARS-CoV-2 specific antibodies were detected on day 7, followed by an increase in titer until day nine that remained elevated on day 20. ASC and T<sub>FH</sub> cell proportion also followed the same kinetics as that of the virus-specific Abs. This study, although limited to one patient, suggests that effective and timely B cell-mediated antibody response might be critical in the recovery of most patients. This is supported by a few reports suggesting that about 70% of non-severe COVID-19 patients have high and persistent SARS-CoV-2 neutralizing antibodies after their recovery (<xref rid="bib174" ref-type="bibr">Wu et al., 2020</xref>). Larger longitudinal cohort studies by Achiron et al. (289 males and 108 females) and Cohen et al. (254 COVID-19 patients) also reported that SARS-CoV-2 neutralizing antibodies persist beyond 9 months post infections, with the persistence of long-lived plasma cells (ASC) and memory B cells (estimated half-life &gt;200 days) conferring long term protective immunity against the re-infection (<xref rid="bib1" ref-type="bibr">Achiron et al., 2021</xref>, <xref rid="bib35" ref-type="bibr">Cohen et al., 2021</xref>). The antibody-mediated protective immunity against SARS-CoV-2 could be due to the following: blocking the binding of the pathogen to the host cells, neutralization of the pathogen, cytotoxicity, and phagocytosis of infected cells (<xref rid="fig0015" ref-type="fig">Fig. 3</xref>). The potential role of the SARS-CoV-2-specific antibody in viral elimination is confirmed by a few <italic toggle="yes">ex-vivo</italic> studies that showed neutralization of the virus by patient-generated antibodies (<xref rid="bib173" ref-type="bibr">Wolfel et al., 2020</xref>, <xref rid="bib190" ref-type="bibr">Zhou et al., 2020a</xref>). Future in-vivo studies would be required to find out the importance and potency of antibody-mediated neutralization of SARS-CoV-2 at different populations and phases of the disease.</p><p id="p0140">Several studies show longitudinal changes in antibody response to SARS-CoV-2 in multiple patients and found significantly elevated levels of Abs during the course of the disease (<xref rid="bib1" ref-type="bibr">Achiron et al., 2021</xref>, <xref rid="bib96" ref-type="bibr">Long et al., 2020</xref>, <xref rid="bib187" ref-type="bibr">Zhao et al., 2020a</xref>). SARS-CoV-2-specific antibodies were detected in &lt;&#8201;40% of patients in the first week after onset of the symptoms, and the level rapidly increased to 100% of patients within 15 days (late stage of infection) (<xref rid="bib187" ref-type="bibr">Zhao et al., 2020a</xref>). Virus-specific antibodies peak appears in 3&#8211;4 weeks post-infection (<xref rid="bib22" ref-type="bibr">Burnett et al., 2021</xref>). Higher level of ASC and virus specific antibodies were observed in many severe patients compared to non-severe patients at late stages of infection (<xref rid="bib22" ref-type="bibr">Burnett et al., 2021</xref>). Surprisingly, the disease worsens as the antibody level increases in the severe group; on the contrary, the disease symptoms improve with increasing antibody levels in the non-severe group (<xref rid="bib96" ref-type="bibr">Long et al., 2020</xref>, <xref rid="bib187" ref-type="bibr">Zhao et al., 2020a</xref>). Some studies have shown that an increased amount of antibody against S-protein and N-protein is correlated positively with the severity of the disease, especially in the elderly patients (<xref rid="bib76" ref-type="bibr">Jiang et al., 2020</xref>, <xref rid="bib163" ref-type="bibr">Tan et al., 2020</xref>).</p><p id="p0145">While some of the analysis suggest nonexistence of antibody-dependent enhancement (ADE) at population level for the disease pathology of SARS-CoV-2 infection (<xref rid="bib53" ref-type="bibr">Gan et al., 2022</xref>). ADE could be one of the contributing factors in patients who becomes quite severe and succumb to death as ADE in monocytes and macrophages can cause hyper inflammation and disease severity in a fraction of patients (<xref rid="bib80" ref-type="bibr">Junqueira et al., 2022</xref>). A recent study identified the potential of certain neutralizing antibodies that have been approved for COVID-19 treatment, to cause ADE (<xref rid="bib110" ref-type="bibr">Mu et al., 2022</xref>). Thus, future studies are required to constantly reevaluate the potential of ADE, especially in the context of new strains of SARS-CoV-2, such as Omicron. There could be many reasons for a potential ADE to occur in the case of current and future sub strains of SARS-CoV-2: first, anti-SARS-CoV-2 non-neutralizing antibodies may activate immune cells through Fc receptor-mediated signaling and start producing pro-inflammatory cytokine (<xref rid="bib75" ref-type="bibr">Iwasaki and Yang, 2020</xref>) causing severe symptoms as shown by Junquira et al., 2022. Second, due to the epitope mimicry, SARS-CoV-2, similar to other coronaviruses (SARS-CoV), can induce the formation of non-specific or autoantibodies which may exacerbate the disease progression by promoting tissue damage, cytokine storm, and aberrant complement activation (<xref rid="bib28" ref-type="bibr">Chang et al., 2021</xref>, <xref rid="bib93" ref-type="bibr">Lin et al., 2005</xref>, <xref rid="bib167" ref-type="bibr">Thurman and Yapa, 2019</xref>). This phenomenon is now well documented in severely ill patients and many studies have identified autoantibodies targeting diverse self-antigens such as angiotensin II (AngII), that regulate blood pressure (<xref rid="bib21" ref-type="bibr">Briquez et al., 2022</xref>), interferons (<xref rid="bib101" ref-type="bibr">Manry et al., 2022</xref>) and nuclear antigens (<xref rid="bib155" ref-type="bibr">Son et al., 2022</xref>). In fact, the presence of autoimmunity is now considered as a hallmark of post covid symptoms including prolonged inflammation, fatigue, and persistence of respiratory symptoms (<xref rid="bib131" ref-type="bibr">Rojas et al., 2022</xref>). The mechanism explained above and beyond might work synergistically to worsen disease outcome. Future studies are required to understand the range of specificity of antibodies and ASCs to SARS-CoV-2 and their potential pathological function in severe patients and patients reporting delayed COVID-19 associated symptoms.</p></sec><sec id="sec0070"><label>4.3</label><title>T cells function in SARS-CoV-2 infected people</title><p id="p0150">CD4<sup>+</sup> T cells primarily regulate adaptive immune response whereas CD8<sup>+</sup> T (cytotoxic T cells) cells directly impart cytotoxicity to the virus-infected cells by producing cell death-inducing molecules such as granzyme, perforin, IFN&#947; (<xref rid="bib142" ref-type="bibr">Schmidt and Varga, 2018</xref>). SARS-CoV-2 reactive T cells were found in recovered COVID-19 patients and a small proportion of seronegative healthy donors, suggesting cross-reactive CD4<sup>+</sup> T cell response to SARS-CoV-2 and common cold coronaviruses, which may account for no or mild symptoms of SARS-CoV-2 infection (<xref rid="bib20" ref-type="bibr">Braun et al., 2020</xref>, <xref rid="bib60" ref-type="bibr">Grifoni et al., 2020</xref>). Kinetic analysis of immune cells and disease states in a 47-year-old patient who recovered from the mild COVID-19 symptoms showed a positive correlation of activated T cells generation and clinical outcome (<xref rid="bib165" ref-type="bibr">Thevarajan et al., 2020</xref>). In this study, the frequency of activated CD4<sup>+</sup> and CD8<sup>+</sup> T cells peaked at the time of viral clearance and then decreased, but the frequency remained higher as compared to healthy control. Interestingly, activated CD8<sup>+</sup> T cells were produced at a higher frequency as compared to activated CD4<sup>+</sup> T cells in severe patients (<xref rid="bib165" ref-type="bibr">Thevarajan et al., 2020</xref>). In contrast, another clinical study has shown that the frequency of IFN&#947; producing activated CD4<sup>+</sup> and CD8<sup>+</sup> T cells remains comparable in both severe and non-severe COVID-19 patients (<xref rid="bib124" ref-type="bibr">Qin et al., 2020</xref>). However, recent reports collectively suggest that activated T cell response may have a more protective role than previously imagined. For example, SARS-CoV-2-specific T cell response is seen in the exposed family members and healthcare workers who were at high-risk and heavily exposed but remained seronegative for antigen (<xref rid="bib39" ref-type="bibr">da Silva Antunes et al., 2021</xref>, <xref rid="bib146" ref-type="bibr">Sekine et al., 2020</xref>), suggesting that T cell response may prevent the establishment of the infection. This is also seen in patients with impaired B cell response, such as cancer patients undergoing B-cell depleting anti-CD20 therapy, where the higher numbers of CD8<sup>+</sup> T cell were found to associated with improved survival (<xref rid="bib13" ref-type="bibr">Bange et al., 2021</xref>). More direct evidence came from the primate model of SARS-CoV-2 infection where the depletion of CD8<sup>+</sup> T cells led to breakthrough SARS-CoV-2 infection, suggesting that CD8<sup>+</sup> T cells protect against reinfection when antibody titers are suboptimal and waning (<xref rid="bib106" ref-type="bibr">McMahan et al., 2020</xref>). Moreover, SARS-CoV-2-specific CD8&#8201;+&#8201;T-cells were found to respond towards multiple nucleocapsid protein domains (<xref rid="bib89" ref-type="bibr">Le Bert et al., 2020</xref>) and are reported in recovered COVID patients (<xref rid="bib89" ref-type="bibr">Le Bert et al., 2020</xref>). The longitudinal studies have suggested the long-term circulation of these T cells contributes to the post-infection immunity (<xref rid="bib113" ref-type="bibr">Nelde et al., 2020</xref>, <xref rid="bib119" ref-type="bibr">Peng et al., 2020</xref>, <xref rid="bib146" ref-type="bibr">Sekine et al., 2020</xref>). SARS-CoV-2 induced alterations in the epigenetic landscape may also play a pivotal role in determining T cell fate and needs further investigation (<xref rid="bib16" ref-type="bibr">Bhat et al., 2022</xref>, <xref rid="bib127" ref-type="bibr">Rha and Shin, 2021</xref>). Considering the kinetic data and other patient-specific scenarios, we may incline to think that the activated CD8<sup>+</sup> T cells that appeared before the clearance of symptoms are directly involved in the killing of the virus-infected cells through the production of granzymes and perforin (<xref rid="bib165" ref-type="bibr">Thevarajan et al., 2020</xref>).</p><p id="p0155">The T cell functions are impaired in severe patients. The cellular mechanism of impaired T cells function in severe disease could be due to the following reasons. First, the proportion of activated T cells is comparable in severe and non-severe patients suggesting the involvement of other immune components with the severity of the disease (<xref rid="bib124" ref-type="bibr">Qin et al., 2020</xref>, <xref rid="bib180" ref-type="bibr">Xu et al., 2020d</xref>). One of the T cells types is the regulatory T cell (Treg), which can restrain other activated T cells&#8217; function (<xref rid="bib135" ref-type="bibr">Sakaguchi et al., 2009</xref>). Severe patients may have significantly reduced Treg cells. In concordance, Qin et al. showed fewer Treg (specifically, induced Treg) in severe patients, thereby failing to restrain other T cell-mediated inflammation and positively contributing to cytokine storm and exacerbation of the disease (<xref rid="bib124" ref-type="bibr">Qin et al., 2020</xref>). Second, the number of T cells or the level of T cell exhaustion may underlie the outcome in the patients. For example, a recent clinical report shows that the numbers of both CD4&#8201;+&#8201;and CD8&#8201;+&#8201;cells were significantly reduced in severely ill patients (<xref rid="bib20" ref-type="bibr">Braun et al., 2020</xref>, <xref rid="bib44" ref-type="bibr">Diao et al., 2020b</xref>), while the recent single cell sequencing data from 39 patients suggests that CD8<sup>+</sup> T cells remains less exhausted in severely ill patients which can cause more cytotoxicity and worsen the outcome (<xref rid="bib85" ref-type="bibr">Kusnadi et al., 2021</xref>). However, some reports also suggest decreased CD8&#8201;+&#8201;T cell number, aberrant activation (<xref rid="bib157" ref-type="bibr">Song et al., 2020</xref>), senescence, and exhaustion in severe COVID patients (<xref rid="bib41" ref-type="bibr">De Biasi et al., 2020</xref>, <xref rid="bib127" ref-type="bibr">Rha and Shin, 2021</xref>), suggesting a complex interplay of T cells in response to SARS-CoV-2 infection. Besides, possibly, T cells that are not specific to the virus are hyperactivated, which can cause disease exacerbation (<xref rid="bib124" ref-type="bibr">Qin et al., 2020</xref>, <xref rid="bib180" ref-type="bibr">Xu et al., 2020d</xref>). <xref rid="fig0015" ref-type="fig">Fig. 3</xref> presents an analysis of lymphocyte counts vs disease severity. Future studies may shed further light on the role of T cells in the non-severe and severe COVID-19 patients.</p></sec><sec id="sec0075"><label>4.4</label><title>Memory lymphocyte generation and function in SARS-CoV-2 infected people</title><p id="p0160">It seems that most of the people who recovered after SARS-CoV-2 infection develop an immune memory. However, the emergence of mutant variants has led to reinfection despite prior infection and vaccination. A large proportion of SARS-CoV-2 infected people harbor long-term memory B and T cells (<xref rid="bib35" ref-type="bibr">Cohen et al., 2021</xref>). Despite memory response, a proportion of prior infected people can get reinfected by the same or a variant of SARS-CoV-2 within a few weeks after recovery (<xref rid="bib7" ref-type="bibr">An et al., 2020</xref>, <xref rid="bib86" ref-type="bibr">Lan et al., 2020</xref>, <xref rid="bib175" ref-type="bibr">Xing et al., 2020a</xref>, <xref rid="bib176" ref-type="bibr">Xing et al., 2020b</xref>). Plausible reinfection would mean an inadequate establishment of immune memory in patients, as a successful establishment of memory would provide long-term protective immunity against viral reinfection. During reinfection, pre-existing protective antibody provides the first line of defense, whereas faster reactivation of pathogen-specific memory lymphocytes provides the second line of defense.</p><p id="p0165">The retrospective analysis shows that reinfected/ relapsed patients were characterized by early RNA negative-conversion in the first infection compared to non-reinfected/ relapsed patients (<xref rid="bib7" ref-type="bibr">An et al., 2020</xref>). It might be possible that short exposure to SARS-CoV-2 (due to a quicker recovery by innate immune response) may not generate an adequate memory in COVID-19. However, the generation of inadequate memory can be much more complicated than just short exposure time, as a significant portion of reinfected/ relapsed patients were young and had non-severe symptoms (<xref rid="bib7" ref-type="bibr">An et al., 2020</xref>, <xref rid="bib86" ref-type="bibr">Lan et al., 2020</xref>, <xref rid="bib176" ref-type="bibr">Xing et al., 2020b</xref>). It is now understood that the primary cause of reinfection was the emergence of newer variants of SARS-CoV-2 (cdc.gov). In the controlled experimental setup, a longitudinal study in the rhesus macaques model showed no recurrence of COVID-19 when the recovered monkeys were re-exposed to SARS-CoV-2 within 28 days of the first infection (<xref rid="bib14" ref-type="bibr">Bao et al., 2020</xref>). This certainly proves the memory response, however, elevated levels of IFN-I and proinflammatory cytokines may also be contributing factors as reinfection is too soon. The duration of memory response for SARS-CoV-2 is determined in a few studies to last beyond 9 months (<xref rid="bib35" ref-type="bibr">Cohen et al., 2021</xref>). Over the past few years, we have learned that the effective memory response wanes over time but still provides protection from the severity of the disease.</p><p id="p0170">A longitudinal (6 years post-infection) study of 23 COVID-recovered patients has shown that all the 23 patients lack SARS-CoV-specific B cells, and 21 of them have undetectable SARS-CoV-specific antibodies. Interestingly, SARS-CoV antigen-specific memory T cell was identified in 60.9% of recovered SARS patients (<xref rid="bib164" ref-type="bibr">Tang et al., 2011</xref>). This study suggests that SARS-CoV infection likely generates a long-term cellular memory but fails to generate a long-standing humoral memory. Another long-term study (up to 11 years) of SARS-CoV-recovered patients showed persistent memory T cells; however, the frequency of T cells varied widely (3.9&#8211;0.2%) after in-vitro expansion (<xref rid="bib115" ref-type="bibr">Ng et al., 2016</xref>). Similarly, Libraty et al. have shown that the frequency of memory T cells significantly declines in SARS-CoV-recovered patients at 12 months post-infection (<xref rid="bib91" ref-type="bibr">Libraty et al., 2007</xref>). Thus, the establishment and frequency of memory T cells significantly varied within the recovered patients&#8217; population and may depend on the severity of the disease. It appears that long-term memory CD4<sup>+</sup> and CD8<sup>+</sup> T cells against SARS-Cov-2 will follow a similar trend as SARS-CoV (<xref rid="bib35" ref-type="bibr">Cohen et al., 2021</xref>). We will continue to learn the duration of adaptive memory in COVID-19-recovered patients when long-term follow-up studies start to pour in (<xref rid="fig0015" ref-type="fig">Fig. 3</xref>). Hopefully, upcoming long-term longitudinal studies will help understand the quality and quantity of immune memory generated in COVID-19-recovered patients.</p></sec></sec><sec id="sec0080"><label>5</label><title>Immune response to SARS-CoV-2 in people with underlying conditions and genetic predisposition</title><p id="p0175">Although the immune response to SARS-CoV-2 may vary among the normal healthy individuals, that may be a determinant for mild and severe symptoms. It is apparent that people with underlying medical conditions and genetic predispositions may cause a dysregulated immune response and are likely to experience severe and life-threatening symptoms. Some pre-existing conditions include age, hypertension, cardiovascular diseases, pulmonary disease, cancer, and obesity, which have been linked to developing severe conditions due to SARS-CoV-2 infection that may lead to more extended hospitalization and death (<xref rid="bib140" ref-type="bibr">Santesmasses et al., 2020</xref>). It is now beginning to unravel how the existence of these comorbidities affects the overall response of the immune system against SARS-CoV-2 infection (<xref rid="bib11" ref-type="bibr">Bajaj et al., 2021</xref>). Among many, age emerged as the most significant risk factor for both contracting the SARS-CoV-2 and worsening of the symptoms (<xref rid="bib140" ref-type="bibr">Santesmasses et al., 2020</xref>). Aging causes changes in the host immune response and decreases the ability to mount an effective immune response to clear infections (<xref rid="bib11" ref-type="bibr">Bajaj et al., 2021</xref>). Recent studies also report the higher expression of ACE-2 in the lungs of aged individuals (<xref rid="bib78" ref-type="bibr">Jin et al., 2022</xref>), which may facilitate a higher propensity to catch an infection. Cancer patients undergoing chemo or radio-therapy may have dysfunctional cytotoxic CD8&#8201;+&#8201;T cells and other immune components (<xref rid="bib147" ref-type="bibr">Shaked, 2019</xref>), which may make them susceptible to infection and exacerbation of the disease progression. Chronic lung illnesses, such as Asthma, Bronchiectasis, Chronic obstructive pulmonary disease, Interstitial lung disease, Pulmonary embolism, and Pulmonary hypertension, are linked with an increased risk of morbidity due to COVID-19 (<xref rid="bib144" ref-type="bibr">Schultze et al., 2020</xref>). Similarly, hypertension can induce CD8&#8201;+T cell exhaustion (<xref rid="bib6" ref-type="bibr">Alexander et al., 2023</xref>), reducing the effector immune cells&#8217; function to control SARS-CoV-2 infection (<xref rid="bib6" ref-type="bibr">Alexander et al., 2023</xref>). COVID-19 comorbidity may also be affected by genetic predisposition, which may aid in determining patient susceptibility and disease severity. A recent in silico study identified several genes, including AGT, FXIIIB, PV92 (<xref rid="bib181" ref-type="bibr">Yamamoto et al., 2021</xref>), LZTFL1, MHC, DPP9, IFNAR2 (<xref rid="bib72" ref-type="bibr">Horowitz et al., 2022</xref>), TLR4, NLRP3, MBL2, IL6, IL1RN, IL1B, CX3CR1, CCR5, and ACE, as possible predictors of disease severity (<xref rid="bib51" ref-type="bibr">Feng et al., 2022</xref>). A more detailed synthesis of the data related to various comorbidities and their association with the COVID-19 outcome has been extensively covered elsewhere (<xref rid="bib17" ref-type="bibr">Bigdelou et al., 2022</xref>, <xref rid="bib71" ref-type="bibr">Honardoost et al., 2021</xref>, <xref rid="bib185" ref-type="bibr">Zhang et al., 2022</xref>).</p></sec><sec id="sec0085"><label>6</label><title>Therapeutic options</title><p id="p0180">As the COVID-19 pandemic is ongoing, the effective treatments are also changing rapidly depending on the currently available information on the new SARS-CoV-2 strains and the success of clinical trials. Currently, multiple lines of treatments are available that can prevent the chances of hospitalization and severity of the disease. These therapeutic strategies can be primarily classified into two groups: first, targeting the SARS-CoV-2 directly using antiviral treatments, and second, targeting the host cells. In the United States, the Food and Drug Administration (FDA) authorized many different antiviral compounds (Nirmatrelevir, Remdesivir, Molnupiravir) that target different parts of the virus and prevent its multiplication in the cells. Another potential and much-hyped experimental antiviral agent Hydroxychloroquine was found to be ineffective in randomized clinical trials with significant side-effects (<xref rid="bib19" ref-type="bibr">Boulware et al., 2020</xref>, <xref rid="bib66" ref-type="bibr">Hennekens et al., 2022</xref>). Here, we focus on the strategies to target the host cells, especially the host immune components. The immune systems can be targeted by two approaches, therapeutic and prophylactic. In the therapeutic approach, the drug is introduced in individual&#8217;s post-infection to restore the immune system during the course of the disease. Pre-infection prophylaxis relies on activating the healthy host-immune systems before infection and onset of the disease. In this review, we will discuss a handful of molecules that were drawing significant attention in treating COVID-19 and the status of whether these molecules eventually pronounced effective in treating COVID-19. The therapeutic molecules encompases IFN-I, JAK/STAT, TNF, IL-1, IL6, GM-CSF, complement, and convalescent serum. The prophylactic molecules to be described here are the vaccine against SARS-CoV-2 antigens and the BCG.</p><sec id="sec0090"><label>6.1</label><title>IFN-I therapies (IFN&#945;, IFN&#946;) and JAK-STAT inhibitors</title><p id="p0185">The anti-viral IFN-I innate immune response is associated with the disease stage, and an early impaired IFN-I response is a critical factor contributing to the progression of COVID-19 pathogenesis. A significant IFN-I response is associated with late cytokine storm in severe COVID-19 patients (discussed in 3.1.1) (<xref rid="bib150" ref-type="bibr">Siddiqi and Mehra, 2020</xref>). Therefore, a therapeutic-staging strategy to activate (Interferon therapy) or inhibit (JAK/ STAT inhibitor) the IFN-I response is warranted. Preclinical and clinical studies suggest an early-stage use of IFN-I treatment, particularly in combination with other antiviral drugs (<xref rid="bib139" ref-type="bibr">Sallard et al., 2020</xref>). The effectiveness of early IFN-I therapy for COVID-19 is supported by an in vitro study showing that, unlike SARS-CoV, SARS-CoV-2 lacks some of the mechanisms to antagonize the IFN-I response (<xref rid="bib95" ref-type="bibr">Lokugamage et al., 2020</xref>, <xref rid="bib139" ref-type="bibr">Sallard et al., 2020</xref>). In concordance, two groups have shown that early IFN-I&#945;/&#946; treatment suppresses SARS-CoV-2 replication in the cell lines (<xref rid="bib95" ref-type="bibr">Lokugamage et al., 2020</xref>, <xref rid="bib102" ref-type="bibr">Mantlo et al., 2020</xref>). In the early stages of the pandemic, a JAK-STAT pathway inhibitor- baricitinib, in combination with the antiviral Remdesivir, was proposed to treat severely ill COVID-19 patients (<xref rid="bib81" ref-type="bibr">Kalil et al., 2021</xref>, <xref rid="bib128" ref-type="bibr">Richardson et al., 2020</xref>). On July, 2021, the FDA approved Baricitinib as a standalone treatment for the severe COVID-19 cases. The updated information of FDA recommended interferon treatments and guidelines can be found on- https://www.covid19treatmentguidelines.nih.gov/.</p></sec><sec id="sec0095"><label>6.2</label><title>Anti-Tumor necrosis factor-alpha therapy</title><p id="p0190">COVID-19 patients have higher TNF-&#945; as compared to healthy controls and are positively correlated with the severity of the disease (<xref rid="bib56" ref-type="bibr">Gong et al., 2020</xref>, <xref rid="bib190" ref-type="bibr">Zhou et al., 2020a</xref>). TNF-&#945; is a proinflammatory cytokine that can amplify inflammation and is associated with viral pathogenesis (<xref rid="bib50" ref-type="bibr">Feldmann et al., 2020</xref>). Anti-TNF therapy shows beneficial effects in a mouse model of respiratory infection and is clinically useful in many inflammatory diseases (<xref rid="bib50" ref-type="bibr">Feldmann et al., 2020</xref>). Thus, the use of a TNF-&#945; inhibitor can potentially reduce the inflammation to prevent the severity of COVID-19. The result of many recent clinical trials suggests that anti-TNF- &#945; treatment has a protective effect on the progression of COVID-19, especially in preventing severe illness (<xref rid="bib62" ref-type="bibr">Guo et al., 2022</xref>). However, due to the potential dampening of the host immune system, anti-TNF- &#945; treatment may result in increased susceptibility to viral and secondary bacterial infections or autoimmune disorders (<xref rid="bib108" ref-type="bibr">Minozzi et al., 2016</xref>), thus the treatment may be most effective for patients with a bleak prognosis. Clinical studies related to different TNF- &#945; inhibitors are listed in
<xref rid="tbl0005" ref-type="table">Table 1</xref>.<table-wrap position="float" id="tbl0005" orientation="portrait"><label>Table 1</label><caption><p>Representative list of some relevant Clinical Trials pertaining to some of the different approaches for the prevention and treatment of COVID-19.</p></caption><alt-text id="at0020">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Sl. No.</th><th colspan="1" rowspan="1">Study Title</th><th colspan="1" rowspan="1">Interventions</th><th colspan="1" rowspan="1">Sponsor/ Collaborators</th><th colspan="1" rowspan="1">NCT Number</th><th colspan="1" rowspan="1">Study duration, Phase (P)</th></tr></thead><tbody><tr><td colspan="6" rowspan="1"><bold>Interferon therapy (IFN&#945;, IFN&#946;) and JAK-STAT inhibitors</bold></td></tr><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">A Study of Baricitinib (LY3009104) in Participants With COVID-19</td><td colspan="1" rowspan="1">Baricitinib</td><td colspan="1" rowspan="1">Eli Lilly and Company</td><td align="char" colspan="1" rowspan="1">04421027</td><td colspan="1" rowspan="1">Jun 2020 &#8211; Jun 2021, P3</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Adaptive COVID-19 Treatment Trial 3 (ACTT-3)</td><td colspan="1" rowspan="1">Interferon Beta 1a, Remdesivir</td><td colspan="1" rowspan="1">National Institute of Allergy and Infectious Diseases (NIAID)</td><td align="char" colspan="1" rowspan="1">04492475</td><td colspan="1" rowspan="1">Aug 2020 &#8211; Dec 2020, P3</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">TOGETHER trial: Effect of Peginterferon Lambda for the Treatment of COVID-19</td><td colspan="1" rowspan="1">Peginterferon Lambda-1A</td><td colspan="1" rowspan="1">University Health Network, Toronto</td><td align="char" colspan="1" rowspan="1">04967430</td><td colspan="1" rowspan="1">Aug 2021 &#8211; Jun 2022, P3</td></tr><tr><td colspan="6" rowspan="1"><bold>Interleukin 1-&#946; therapy</bold></td></tr><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">SAVE-MORE trial: suPAR-Guided Anakinra Treatment for Management of Severe Respiratory Failure by COVID-19</td><td colspan="1" rowspan="1">Anakinra; blocks IL-1&#945; and IL-1&#946;</td><td colspan="1" rowspan="1">Hellenic Institute for the Study of Sepsis</td><td align="char" colspan="1" rowspan="1">04680949</td><td colspan="1" rowspan="1">Dec 2020 &#8211; Feb 2022, P3</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Treatment of COVID-19 Patients With Anti-interleukin Drugs</td><td colspan="1" rowspan="1">Anakinra, Siltuximab, and Tocilizumab</td><td colspan="1" rowspan="1">University Hospital, Ghent<break/>Belgium Health Care Knowledge Centre</td><td align="char" colspan="1" rowspan="1">04330638</td><td colspan="1" rowspan="1">Apr 2020 &#8211; Apr 2021, P3</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">CAN-COVID trial. Treatment of COVID-19 Patients With Anti-interleukin Drugs</td><td colspan="1" rowspan="1">Canakinumab</td><td colspan="1" rowspan="1">Novartis Pharmaceuticals</td><td align="char" colspan="1" rowspan="1">04362813</td><td colspan="1" rowspan="1">Apr 2020 - Dec 2020, P3</td></tr><tr><td colspan="6" rowspan="1"><bold>Anti-Tumor necrosis factor-alpha therapy</bold></td></tr><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury</td><td colspan="1" rowspan="1">XPro1595</td><td colspan="1" rowspan="1">Inmune Bio, Inc.</td><td align="char" colspan="1" rowspan="1">04370236</td><td colspan="1" rowspan="1">Jun 2020 &#8211; Jan 2021, P2</td></tr><tr><td colspan="6" rowspan="1"><bold>IL-6 inhibitor</bold></td></tr><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection</td><td colspan="1" rowspan="1">Clazakizumab</td><td colspan="1" rowspan="1">NYU Langone Health</td><td align="char" colspan="1" rowspan="1">04343989</td><td colspan="1" rowspan="1">Mar 2020 &#8211; Mar 2021, P2</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">EMPACTA trial: Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</td><td colspan="1" rowspan="1">Tocilizumab (anti- IL-6 receptor Ab)</td><td colspan="1" rowspan="1">Hoffmann-La Roche</td><td align="char" colspan="1" rowspan="1">04320615</td><td colspan="1" rowspan="1">Apr 2020 &#8211; Jul 2020</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis</td><td colspan="1" rowspan="1">Sirolimus</td><td colspan="1" rowspan="1">University of Chicago</td><td align="char" colspan="1" rowspan="1">04948203</td><td colspan="1" rowspan="1">Jul 2021 - Jul 2024, P3</td></tr><tr><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">Sarilumab COVID-19</td><td colspan="1" rowspan="1">Sarilumab</td><td colspan="1" rowspan="1">Sanofi<break/>Regeneron Pharmaceuticals</td><td align="char" colspan="1" rowspan="1">04327388</td><td colspan="1" rowspan="1">Mar 2020 &#8211; Sept 2020, P3</td></tr></tbody></table></table-wrap></p></sec><sec id="sec0100"><label>6.3</label><title>Interleukin 1-&#946; therapy</title><p id="p0195">COVID-19 patients have a higher level of IL-1&#946; as compared to healthy control and are an important mediator of the inflammatory response (<xref rid="bib190" ref-type="bibr">Zhou et al., 2020a</xref>). Higher IL-1&#946; level is associated with autoinflammatory diseases, and the use of an anti-IL-1&#946; receptor blocker (anakinara) or a drug that blocks IL-1 signaling (mAb Canakinumab) are shown to be beneficial in managing COVID-19 (<xref rid="bib45" ref-type="bibr">Dinarello et al., 2012</xref>). Thus, the use of an IL-1&#946; inhibitor can potentially reduce the inflammation and severity of COVID-19. On November 8, 2022, the FDA approved the use of anakinara in selected severely ill COVID-19 patients (under emergency use authorization). More information related to the updated status of IL-1 targeting therapies can be found at https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/interleukin-1-inhibitors/. Some of the notable current trials are shown in <xref rid="tbl0005" ref-type="table">Table 1</xref>. Caution must be practiced in choosing the patients as the use of an IL-1&#946; inhibitor can dampen the host&#8217;s immunity to fight some other types of infections.</p></sec><sec id="sec0105"><label>6.4</label><title>Complement proteins Inhibitors</title><p id="p0200">Activated complement proteins are present at elevated levels in severe patients; inhibiting these activated complement proteins may reduce the innate immune-mediated consequences. A combination strategy may include a complement inhibitor combined with anti-viral therapeutics. In the past, complement inhibition has provided favorable outcomes in SARS-CoV and MERS-CoV murine models (<xref rid="bib77" ref-type="bibr">Jiang et al., 2018</xref>, <xref rid="bib160" ref-type="bibr">Sun et al., 2013</xref>). The success of anti-C5a therapy in mouse models of influenza virus and MERS-CoV have led to the development of humanized monoclonal antibodies against the human C5a protein by at least two pharmaceutical companies (US-based Alexion and Germany-based InflaRx). Various clinical trials for evaluating complement system therapies are underway, and it is still early to conclude how effective the complement-targeting therapies would be for severely ill COVID-19 patients (<xref rid="bib2" ref-type="bibr">Afzali et al., 2021</xref>).</p></sec><sec id="sec0110"><label>6.5</label><title>IL-6 inhibitor</title><p id="p0205">IL6 is one of the major constituents of the cytokine storm in severe COVID-19 patients, and therefore, it is proposed that blockade of IL-6 in COVID-19 patients may ameliorate the COVID-19 associated symptoms (<xref rid="bib124" ref-type="bibr">Qin et al., 2020</xref>). Initial clinical trials using IL-6 inhibitors in the treatment of COVID-19 have been promising. Although the precise mechanism by which IL6 inhibitor may control COVID-19 progression is not well understood, inhibition of IL-6 may likely reduce the IL-6-mediated inflammatory response, including reduced production of Th17 cells and restoration of lymphopoiesis and myelopoiesis balance (<xref rid="bib180" ref-type="bibr">Xu et al., 2020d</xref>); (<xref rid="bib117" ref-type="bibr">Pedersen and Ho, 2020</xref>, <xref rid="bib124" ref-type="bibr">Qin et al., 2020</xref>). Some of the interesting clinical trials assessing the use of IL-6 inhibitors are mentioned in <xref rid="tbl0005" ref-type="table">Table 1</xref>. Promising clinical benefits with reduced mortality, decreased requirement for assisted breathing, and minimized hospitalization have been observed using an IL-6 receptor inhibitor in severe COVID-19 patients (REMAP-CAP and RECOVERY trials). These promising findings resulted in the FDA approval (Dec 2022) of IL-6 targeting therapies that use human monoclonal antibodies against IL-6 receptors (Tocilizumab). This approval is for the use of intravenous (IV) tocilizumab for the treatment of COVID-19 hospitalized adults receiving systemic corticosteroids and need supplemental oxygen, noninvasive ventilation (NIV), mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). On the other hand, some trials showed some advantages but did not yield statistically relevant positive results with IL-6 inhibitors for survivability (COVACTA and EMPACTA trials) (<xref rid="bib134" ref-type="bibr">Rubin et al., 2021</xref>). Tocilizumab's usage in conjunction with other therapies, such as corticosteroids and Remdesevir, is also studied. The recent REMDACTA trial attempted the combined use of Tocilizumab and Remdesevir but did not yield a significant survival advantage compared to Remdesevir alone. The CORIMUNO-19 study group conducted a clinical trial with Dexamethasone and Tocilizumab compared to Dexamethasone alone, but did not find advantages with ventilation support and mortality (<xref rid="bib68" ref-type="bibr">Hermine et al., 2022</xref>). Several studies corroborate the potential effects of IL-6 inhibitors, however, some studies also present tricky concerns, making their optimal use challenging and demanding further examination. More information regarding IL-6 inhibitors can be found at https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/interleukin-6-inhibitors/.</p></sec><sec id="sec0115"><label>6.6</label><title>Granulocyte macrophage colony-stimulating factor (GM-CSF) inhibitor</title><p id="p0210">It has been shown that severe COVID-19 patients generate GM-CSF producing CD4<sup>+</sup> T cells (<xref rid="bib190" ref-type="bibr">Zhou et al., 2020a</xref>). GM-CSF plays a key role in hematopoiesis and is essential for the generation of inflammatory (CD14<sup>+</sup>CD16<sup>+</sup>) monocytes that are associated with COVID-19 disease severity. Thus, the use of a GM-CSF inhibitor can potentially reduce the generation of inflammatory monocytes to prevent the severity of COVID-19. Multiple antibodies targeting GM-CSF are currently under clinical trial (e.g., <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04341116">NCT04341116</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04351152">NCT04351152</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04376684">NCT04376684</ext-link>) (<xref rid="bib120" ref-type="bibr">Perricone et al., 2020</xref>). Lenzilumab reduces immune hyperstimulation and improves clinical outcomes in high-risk COVID-19 patients. GM-CSF&#945; antagonist Mavrilimumab improves clinical outcomes in COVID-19 patients with severe pneumonia (<xref rid="bib84" ref-type="bibr">Kohler and Conway Morris, 2023</xref>). The trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04351243">NCT04351243</ext-link>) using the Mab Gimsilumab for targeting COVID-19 pneumonia did not yield convincing results (<xref rid="bib37" ref-type="bibr">Criner et al., 2022</xref>). In the OSCAR study, the anti&#8211;GM-CSF monoclonal antibody Otilimab was evaluated (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04376684">NCT04376684</ext-link>). Otilimab is related to clinical improvements and slower progression, although there is no meaningful difference at Day 28 in the percentage of patients who are alive and devoid of respiratory distress (<xref rid="bib116" ref-type="bibr">Patel et al., 2023</xref>). Thus, divergent data have emerged for or against using GM-CSF inhibitors for COVID-19. In addition, the precise mechanism of this niche-specific and temporal influence on the incidence of COVID pathology is unclear, as is whether it plays a bystander function. The potential benefit could be the restoration of anti-viral immunity and prevention of secondary infection in very severe ARDS COVID-19 cases, but at the same time, well-planned randomized, double-blind, placebo-controlled trials are needed.</p></sec><sec id="sec0120"><label>6.7</label><title>Convalescent Plasma</title><p id="p0215">Convalescent plasma (CP) as passive immune therapy has been used for more than a century to prevent and treat infectious diseases. CP from recovered COVID-19 patients can provide SARS-CoV-2-specific neutralizing antibodies as a therapeutic intervention to new SARS-CoV-2 infected patients or as prophylactic for individuals with a high risk of contracting COVID-19 (<xref rid="bib26" ref-type="bibr">Casadevall and Pirofski, 2020</xref>). The use of CP in severe COVID-19 patients has shown significant improvements in clinical outcomes in several independent studies (<xref rid="bib9" ref-type="bibr">Arnold Egloff et al., 2021</xref>, <xref rid="bib46" ref-type="bibr">Duan et al., 2020</xref>, <xref rid="bib92" ref-type="bibr">Libster et al., 2021</xref>, <xref rid="bib137" ref-type="bibr">Salazar et al., 2020</xref>). Many clinical trials with larger cohorts have tested prophylaxis and therapeutic protocols against COVID-19 in randomized clinical trials and found contradictory outcomes. Nevertheless, other investigations comparing CP with neutralizing anti-SARS-CoV-2 antibodies to placebo revealed no benefit in COVID-19 hospitalized patients (<xref rid="bib34" ref-type="bibr">Cho et al., 2021</xref>, <xref rid="bib151" ref-type="bibr">Simonovich et al., 2021</xref>, <xref rid="bib156" ref-type="bibr">Song et al., 2022</xref>). A group of companies has joined hands to develop a polyclonal antibody product: hyperimmune globulin (H-Ig) purified from the pooled plasma of COVID-19-recovered patients. SAb Biotherapeutics and the US Biomedical Advanced Research and Development Authority are collaborating to capture the entire human antibody repertoire against SARS-CoV-2 using a recombinant platform (<xref rid="bib149" ref-type="bibr">Sheridan, 2020</xref>). At the initial stages of COVID-19 CP became a popular choice due to the inherent benefits, as CP was readily available, needed no significant research time to initiate trials, is polyclonal, inexpensive, accessible even in resource-limited nations, and recovering COVID convalescing survivors were available. CP also suffered from several critical pitfalls in the large-scale clinical applications of CP, including source, handling, determination of neutralizing antibodies titer, screening for transmissible pathogens and effectiveness of pathogen neutralization. Considering the conflicting data from different trails, FDA updated the guidelines for using only CPs with high-titer of anti-SARS-CoV-2 antibodies for immunosuppressant patients. The updated information on CP-based therapy can be found on the following website: https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/covid-19-convalescent-plasma/.</p></sec><sec id="sec0125"><label>6.8</label><title>SARS-CoV-2 specific vaccine</title><p id="p0220">Within three years after SARS-CoV-2 was first identified in Wuhan, many effective vaccines got developed through public-private partnerships in many countries. We now have many effective vaccines with proven efficacy. Globally, a massive vaccination drive has helped curb the infection, disease severity, and death rate due to SARS-Cov-2. As per WHO, 13,168,935,724 vaccines have been administered worldwide. The identification of the genetic sequence of SARS-CoV-2 has led to vaccine designs using traditional and new approaches to combat the disease. SARS-CoV-2 has a total of 11 structural and non-structural proteins (<xref rid="bib79" ref-type="bibr">Jin et al., 2020</xref>). Spike protein was identified as the most appropriate vaccine antigen, which formed the backbone for most popular mRNA-based vaccine developed independently by &#8220;Moderna&#8221;, and &#8220;Bio-Ntech &amp; Pfizer&#8221;. The race to develop effective vaccines started when a study showed that the inactivated SARS-CoV-2 virus provides protective immunity in monkeys (<xref rid="bib54" ref-type="bibr">Gao et al., 2020a</xref>). The current vaccine development landscape now offers several technology platforms, including SARS-CoV-2 nucleic acid-based (DNA-ZyCoV-D, and RNA-Moderna, BioNTech/Pfizer), virus-spike protein subunit vaccine (Novavax), a replication-incompetent viral carrying the viral gene (AstraZeneca, Sputnik V, Janssen), live whole attenuated virus (COVI-VAC, under trails) (<xref rid="bib32" ref-type="bibr">Chen et al., 2022</xref>, <xref rid="bib94" ref-type="bibr">Liu et al., 2022</xref>) and inactivated whole virus (Valneva-VLA2001, under trails) (<xref rid="bib88" ref-type="bibr">Lazarus et al., 2022</xref>). More detailed information on the currently approved/ under trial COVID-19 vaccines is available at the link (https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_12January2023.pdf). In addition to the antigen, various antigen delivery strategies are also being used for generating a better SARS-CoV-2 vaccine response. These methods include microneedle patches to deliver pieces of the spike protein via the skin (<xref rid="bib83" ref-type="bibr">Kim et al., 2020</xref>), intramuscular injections (most vaccines), and nasal sprays (<xref rid="bib170" ref-type="bibr">Waltz, 2022</xref>). Both Moderna and Pfizer mRNA vaccines use lipid nanoparticles for the delivery of mRNAs for the SARS-CoV-2 spike protein.</p><p id="p0225">It appears that a multi-epitope vaccine designed using immunoinformatic and molecular modeling approaches for epitopes from multiple proteins could be a useful vaccine development strategy in the future (<xref rid="bib104" ref-type="bibr">Martin and Cheng, 2021</xref>, <xref rid="bib129" ref-type="bibr">Robson, 2020</xref>, <xref rid="bib158" ref-type="bibr">Srivastava et al., 2020</xref>; ul <xref rid="bib123" ref-type="bibr">Qamar et al., 2020</xref>). A multi-epitope vaccine increases the diversity of the immune repertoire and might be effective in providing protective immunity against genetically different variants of SARS-CoV-2. However, antibodies generated against these epitopes have a risk of mounting an ADE that needs to be appropriately evaluated (<xref rid="bib118" ref-type="bibr">Peeples, 2020</xref>). With the emergence of new strains of SARS-CoV-2, next-generation of bivalent vaccines have been rolled out that are available in the form of &#8220;boosters&#8221; at specific intervals. These booster vaccines contain components of the original virus strain and the recently identified omicron variant to ensure widespread protection against diverse SARS-CoV-2 strains in circulation. The Moderna and Pfizer-BioNTech bivalent COVID-19 vaccines are FDA-approved to be administered as a solitary booster dose. On December 2022, Pfizer-BioNTech released COVID-19 vaccination for children aged 6 months - 4 years, thus covering almost the entire population range. These boosters activate the memory B cells that had been formed since the first vaccine dose and boost antibody production, thus extending the immunity against SARS-CoV-2 (<xref rid="bib111" ref-type="bibr">Muecksch et al., 2022</xref>). More information on the status of boosters is available at https://www.cds.gov. The continuous process of complex viral evolution emphasizes the need to update the vaccine pipeline to improve vaccine effectiveness, followed by rigorous tracking and careful study design to better understand the preventive role of vaccine-derived immunity versus immunogenic protection from prior infection, and "hybrid" immunity.</p></sec><sec id="sec0130"><label>6.9</label><title>BCG Vaccine</title><p id="p0230">Many epidemiological studies have found a very good correlation between childhood Bacillus Calmette-Gu&#233;rin (BCG) vaccination and a lower incidence and death rate from COVID-19 (<xref rid="bib107" ref-type="bibr">Miller, 2020</xref>). It can be speculated that the BCG vaccine activates metabolic and epigenetic alterations to stimulate the innate immune response that can protect from subsequent infections by viruses, including SARS-CoV-2, via a process termed as &#8220;trained immunity&#8221; (<xref rid="bib38" ref-type="bibr">Curtis et al., 2020</xref>, <xref rid="bib114" ref-type="bibr">Netea et al., 2020</xref>). Antigen-independent bystander B and T cell activation may also confer protection (<xref rid="bib58" ref-type="bibr">Goodridge et al., 2016</xref>). Several clinical trials are testing the power of trained immunity via the use of the BCG vaccine against COVID-19 (e.g., <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04328441">NCT04328441</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04327206">NCT04327206</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04348370">NCT04348370</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04369794">NCT04369794</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04328441">NCT04328441</ext-link>); (<xref rid="bib38" ref-type="bibr">Curtis et al., 2020</xref>). However, it should be noted that many recent reports show that BCG vaccination offers no advantage against SARS-CoV-2 infection (<xref rid="bib65" ref-type="bibr">Hamiel et al., 2020</xref>, <xref rid="bib168" ref-type="bibr">Upton et al., 2022</xref>). The BCG vaccine-mediated non-specific heterologous protection may temporarily bring hope, especially when no preventive tools are available (<xref rid="bib57" ref-type="bibr">Gonzalez-Perez et al., 2021</xref>) (<xref rid="bib125" ref-type="bibr">Redelman-Sidi, 2020</xref>). Another aspect is whether BCG vaccination can protect people with underlying conditions. A recent trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02081326">NCT02081326</ext-link>) demonstrated that multi-dose BCG immunizations could provide platform protection to susceptible type 1 diabetes patients against COVID-19 and other infections (<xref rid="bib49" ref-type="bibr">Faustman et al., 2022</xref>). However, until confounding results are published and evaluated, careful monitoring should be practiced as the upregulation of immunity may activate COVID symptoms in some patients.</p></sec></sec><sec id="sec0135"><label>7</label><title>Conclusion</title><p id="p0235">In this review, we have attempted to capture the heterogeneity and complexity of the hosts&#8217; immune responses in SARS-CoV-2-infected people. We have presented a proposed kinetics of disease severity, major symptoms, and immune response in mild/ moderate vs. severe (survivors and nonsurvivors) (<xref rid="fig0015" ref-type="fig">Fig. 3</xref>). We have discussed the potential mechanisms pertaining to the protective and pathogenic immune responses in &#8220;mild/ moderate&#8221; and &#8220;severe&#8221; symptomatic COVID-19 patients, respectively. Furthermore, we discuss potential therapeutic options to target the immune components for the treatment of severe COVID-19 patients. The dysregulation of the immune system during severe COVID-19 disease involves (1) impaired early IFN-I production, (2) excess cytokine production, (3) uncontrolled activation of complement systems, (4) increased neutrophils, and reduced lymphocytes number, (5) production of pathogenic antibody in a few severe patients, (6) reduced Treg number, (7) impaired memory lymphocytes formation. So far, current data suggest that individuals with weak immune systems (older adults and people with chronic medical illnesses) have a higher propensity to develop a severe form of the disease. On the contrary, severely ill patients show a cytokine storm, which might be an indication of hyperactivated immune systems. Future time course studies are required to understand the progression of the immune response in severe conditions. Detailed studies in suitable model systems have helped decipher some of the cellular and molecular mechanisms of the immune responses that could be happening during the spectrum of COVID-19. Future studies will be important to understand the mechanism underlying the severe and non-severe COVID-19 conditions.</p></sec></body><back><ref-list id="bibliog0005"><title>References</title><ref id="bib1"><element-citation publication-type="journal" id="sbref1"><person-group person-group-type="author"><name name-style="western"><surname>Achiron</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mandel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dreyer-Alster</surname><given-names>S.</given-names></name><name name-style="western"><surname>Harari</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dolev</surname><given-names>M.</given-names></name><name name-style="western"><surname>Menascu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Magalashvili</surname><given-names>D.</given-names></name><name name-style="western"><surname>Flechter</surname><given-names>S.</given-names></name><name name-style="western"><surname>Givon</surname><given-names>U.</given-names></name><name name-style="western"><surname>Guber</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study</article-title><source>J. Neuroimmunol.</source><year>2021</year><fpage>361</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jneuroim.2021.577746</pub-id><pub-id pub-id-type="pmcid">PMC8500842</pub-id><pub-id pub-id-type="pmid">34655991</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal" id="sbref2"><person-group person-group-type="author"><name name-style="western"><surname>Afzali</surname><given-names>B.</given-names></name><name name-style="western"><surname>Noris</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lambrecht</surname><given-names>B.N.</given-names></name><name name-style="western"><surname>Kemper</surname><given-names>C.</given-names></name></person-group><article-title>The state of complement in COVID-19</article-title><source>Nat. Rev. Immunol.</source><volume>22</volume><year>2021</year><fpage>77</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">34912108</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-021-00665-1</pub-id><pub-id pub-id-type="pmcid">PMC8672651</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal" id="sbref3"><person-group person-group-type="author"><name name-style="western"><surname>Agrawal</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nawadkar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ojha</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sahu</surname><given-names>A.</given-names></name></person-group><article-title>Complement Evasion Strategies of Viruses: An Overview</article-title><source>Front. Microbiol.</source><year>2017</year><fpage>8</fpage><pub-id pub-id-type="pmid">28670306</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmicb.2017.01117</pub-id><pub-id pub-id-type="pmcid">PMC5472698</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal" id="sbref4"><person-group person-group-type="author"><name name-style="western"><surname>Akhmerov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marban</surname><given-names>E.</given-names></name></person-group><article-title>COVID-19 and the Heart</article-title><source>Circ. Res</source><volume>126</volume><year>2020</year><fpage>1443</fpage><lpage>1455</lpage><pub-id pub-id-type="pmid">32252591</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCRESAHA.120.317055</pub-id><pub-id pub-id-type="pmcid">PMC7188058</pub-id></element-citation></ref><ref id="bib5"><mixed-citation publication-type="other" id="othref0005">Aleem, A., Akbar Samad, A.B., Slenker, A.K. , 2022. Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19). In StatPearls (Treasure Island (FL)).<pub-id pub-id-type="pmid">34033342</pub-id></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="other" id="othref0010">Alexander, M.R., Dale, B.L., Smart, C.D., Elijovich, F., Wogsland, C.E., Lima, S.M., Irish, J.M., Madhur, M.S. , 2023. Immune Profiling Reveals Decreases in Circulating Regulatory and Exhausted T Cells in Human Hypertension. JACC: Basic to Translational Science.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacbts.2022.09.007</pub-id><pub-id pub-id-type="pmcid">PMC10077123</pub-id><pub-id pub-id-type="pmid">37034287</pub-id></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="other" id="othref0015">An, J., Liao, X., Xiao, T., Qian, S., Yuan, J., Ye, H., Qi, F., Shen, C., Liu, Y., Wang, L.<italic toggle="yes">,</italic> et al.&#160;, 2020.</mixed-citation></ref><ref id="bib8"><element-citation publication-type="journal" id="sbref5"><person-group person-group-type="author"><name name-style="western"><surname>Annane</surname><given-names>D.</given-names></name><name name-style="western"><surname>Heming</surname><given-names>N.</given-names></name><name name-style="western"><surname>Grimaldi-Bensouda</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fr&#233;meaux-Bacchi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Vigan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Roux</surname><given-names>A.-L.</given-names></name><name name-style="western"><surname>Marchal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Michelon</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rottman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moine</surname><given-names>P.</given-names></name></person-group><article-title>Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: a proof-of-concept study</article-title><source>EClinicalMedicine</source><year>2020</year><fpage>28</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2020.100590</pub-id><pub-id pub-id-type="pmcid">PMC7644240</pub-id><pub-id pub-id-type="pmid">33173853</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal" id="sbref6"><person-group person-group-type="author"><name name-style="western"><surname>Arnold Egloff</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Junglen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Restivo</surname><given-names>J.S.A.</given-names></name><name name-style="western"><surname>Wongskhaluang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Doshi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Schlauch</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fromell</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sears</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Correll</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19</article-title><source>J. Clin. Investig.</source><year>2021</year><fpage>131</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI151788</pub-id><pub-id pub-id-type="pmcid">PMC8516450</pub-id><pub-id pub-id-type="pmid">34464352</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal" id="sbref7"><person-group person-group-type="author"><name name-style="western"><surname>Asadi-Pooya</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Simani</surname><given-names>L.</given-names></name></person-group><article-title>Central nervous system manifestations of COVID-19: a systematic review</article-title><source>J. Neurol. Sci.</source><volume>413</volume><year>2020</year><object-id pub-id-type="publisher-id">116832</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jns.2020.116832</pub-id><pub-id pub-id-type="pmcid">PMC7151535</pub-id><pub-id pub-id-type="pmid">32299017</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal" id="sbref8"><person-group person-group-type="author"><name name-style="western"><surname>Bajaj</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gadi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Spihlman</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Moulton</surname><given-names>V.R.</given-names></name></person-group><article-title>Aging, immunity, and COVID-19: how age influences the host immune response to coronavirus infections</article-title><source>Front. Physiol.</source><year>2021</year><fpage>11</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphys.2020.571416</pub-id><pub-id pub-id-type="pmcid">PMC7835928</pub-id><pub-id pub-id-type="pmid">33510644</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal" id="sbref9"><person-group person-group-type="author"><name name-style="western"><surname>Banerjee</surname><given-names>R.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>P.</given-names></name><name name-style="western"><surname>Das</surname><given-names>S.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>M.K.</given-names></name></person-group><article-title>A hybrid model integrating warm heat and ultraviolet germicidal irradiation might efficiently disinfect respirators and personal protective equipment</article-title><source>Am. J. Infect. Control</source><volume>49</volume><year>2021</year><fpage>309</fpage><lpage>318</lpage><pub-id pub-id-type="pmid">32735810</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajic.2020.07.022</pub-id><pub-id pub-id-type="pmcid">PMC7386295</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal" id="sbref10"><person-group person-group-type="author"><name name-style="western"><surname>Bange</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Han</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Wileyto</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Gouma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Greenplate</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Hwee</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Porterfield</surname><given-names>F.</given-names></name><name name-style="western"><surname>Owoyemi</surname><given-names>O.</given-names></name><etal/></person-group><article-title>CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer</article-title><source>Nat. Med.</source><volume>27</volume><year>2021</year><fpage>1280</fpage><lpage>1289</lpage><pub-id pub-id-type="pmid">34017137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-021-01386-7</pub-id><pub-id pub-id-type="pmcid">PMC8291091</pub-id></element-citation></ref><ref id="bib14"><mixed-citation publication-type="other" id="othref0020">Bao, L., Deng, W., Gao, H., Xiao, C., Liu, J., Xue, J., Lv, Q., Liu, J., Yu, P., Xu, Y.<italic toggle="yes">,</italic> et al.&#160;, 2020.</mixed-citation></ref><ref id="bib15"><element-citation publication-type="journal" id="sbref11"><person-group person-group-type="author"><name name-style="western"><surname>Bastard</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Michailidis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>H.-H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dorgham</surname><given-names>K.</given-names></name><name name-style="western"><surname>Philippot</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Rosain</surname><given-names>J.</given-names></name><name name-style="western"><surname>B&#233;ziat</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Autoantibodies against type I IFNs in patients with life-threatening COVID-19</article-title><source>Science</source><year>2020</year><fpage>370</fpage><pub-id pub-id-type="pmid">32972996</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abd4585</pub-id><pub-id pub-id-type="pmcid">PMC7857397</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal" id="sbref12"><person-group person-group-type="author"><name name-style="western"><surname>Bhat</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rishi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chadha</surname><given-names>V.D.</given-names></name></person-group><article-title>Understanding the epigenetic mechanisms in SARS CoV-2 infection and potential therapeutic approaches</article-title><source>Virus Res.</source><year>2022</year><fpage>318</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.virusres.2022.198853</pub-id><pub-id pub-id-type="pmcid">PMC9236910</pub-id><pub-id pub-id-type="pmid">35777502</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal" id="sbref13"><person-group person-group-type="author"><name name-style="western"><surname>Bigdelou</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sepand</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Najafikhoshnoo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Negrete</surname><given-names>J.A.T.</given-names></name><name name-style="western"><surname>Sharaf</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>J.Q.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>I.</given-names></name><name name-style="western"><surname>Chauhan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Etter</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shekarian</surname><given-names>T.</given-names></name><etal/></person-group><article-title>COVID-19 and preexisting comorbidities: risks, synergies, and clinical outcomes</article-title><source>Front. Immunol.</source><year>2022</year><fpage>13</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2022.890517</pub-id><pub-id pub-id-type="pmcid">PMC9196863</pub-id><pub-id pub-id-type="pmid">35711466</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal" id="sbref14"><person-group person-group-type="author"><name name-style="western"><surname>Bosmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>P.A.</given-names></name></person-group><article-title>Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis</article-title><source>Adv. Exp. Med Biol.</source><volume>946</volume><year>2012</year><fpage>147</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">21948367</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-4614-0106-3_9</pub-id><pub-id pub-id-type="pmcid">PMC3372066</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal" id="sbref15"><person-group person-group-type="author"><name name-style="western"><surname>Boulware</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Pullen</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Bangdiwala</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Pastick</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Lofgren</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Okafor</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Skipper</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Nascene</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Nicol</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Abassi</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A randomized trial of hydroxychloroquine as postexposure prophylaxis for covid-19</article-title><source>N. Engl. J. Med.</source><volume>383</volume><year>2020</year><fpage>517</fpage><lpage>525</lpage><pub-id pub-id-type="pmid">32492293</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2016638</pub-id><pub-id pub-id-type="pmcid">PMC7289276</pub-id></element-citation></ref><ref id="bib20"><mixed-citation publication-type="other" id="othref0025">Braun, J., Loyal, L., Frentsch, M., Wendisch, D., Georg, P., Kurth, F., Hippenstiel, S., Dingeldey, M., Kruse, B., Fauchere, F.<italic toggle="yes">,</italic> et al.&#160;, 2020.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2598-9</pub-id><pub-id pub-id-type="pmid">32726801</pub-id></mixed-citation></ref><ref id="bib21"><element-citation publication-type="journal" id="sbref16"><person-group person-group-type="author"><name name-style="western"><surname>Briquez</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Rouhani</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pyzer</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Trujillo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dugan</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Stamper</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Changrob</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sperling</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>P.C.</given-names></name><etal/></person-group><article-title>Severe COVID-19 induces autoantibodies against angiotensin II that correlate with blood pressure dysregulation and disease severity</article-title><source>Sci. Adv.</source><year>2022</year><fpage>8</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.abn3777</pub-id><pub-id pub-id-type="pmcid">PMC9544317</pub-id><pub-id pub-id-type="pmid">36206332</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal" id="sbref17"><person-group person-group-type="author"><name name-style="western"><surname>Burnett</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>K.J.L.</given-names></name><name name-style="western"><surname>Langley</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Aggarwal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stella</surname><given-names>A.O.</given-names></name><name name-style="western"><surname>Johansen</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Balachandran</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lenthall</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rouet</surname><given-names>R.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability</article-title><source>Immunity</source><volume>54</volume><issue>2908&#8211;2921</issue><year>2021</year><object-id pub-id-type="publisher-id">e2906</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2021.10.019</pub-id><pub-id pub-id-type="pmcid">PMC8554075</pub-id><pub-id pub-id-type="pmid">34788600</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal" id="sbref18"><person-group person-group-type="author"><name name-style="western"><surname>Callaway</surname><given-names>E.</given-names></name></person-group><article-title>Coronavirus variant XBB.1.5 rises in the United States &#8212; is it a global threat?</article-title><source>Nature</source><volume>613</volume><year>2023</year><fpage>222</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">36624320</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41586-023-00014-3</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal" id="sbref19"><person-group person-group-type="author"><name name-style="western"><surname>Campbell</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Kahwash</surname><given-names>R.</given-names></name></person-group><article-title>Will complement inhibition be the new target in treating COVID-19 related systemic thrombosis?</article-title><source>Circulation</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.120.047419</pub-id><pub-id pub-id-type="pmid">32271624</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal" id="sbref20"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>X.</given-names></name></person-group><article-title>COVID-19: immunopathology and its implications for therapy</article-title><source>Nat. Rev. Immunol.</source><volume>20</volume><year>2020</year><fpage>269</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">32273594</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-020-0308-3</pub-id><pub-id pub-id-type="pmcid">PMC7143200</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal" id="sbref21"><person-group person-group-type="author"><name name-style="western"><surname>Casadevall</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pirofski</surname><given-names>L.A.</given-names></name></person-group><article-title>The convalescent sera option for containing COVID-19</article-title><source>J. Clin. Invest</source><volume>130</volume><year>2020</year><fpage>1545</fpage><lpage>1548</lpage><pub-id pub-id-type="pmid">32167489</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI138003</pub-id><pub-id pub-id-type="pmcid">PMC7108922</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal" id="sbref22"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kok</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>To</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yip</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Poon</surname><given-names>R.W.</given-names></name><etal/></person-group><article-title>A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>514</fpage><lpage>523</lpage><pub-id pub-id-type="pmid">31986261</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30154-9</pub-id><pub-id pub-id-type="pmcid">PMC7159286</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal" id="sbref23"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>A.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Apostolidis</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Mack</surname><given-names>E.</given-names></name><name name-style="western"><surname>Artandi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Barman</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chakraborty</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>I.</given-names></name><etal/></person-group><article-title>New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nature</article-title><source>Communications</source><year>2021</year><fpage>12</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-021-25509-3</pub-id><pub-id pub-id-type="pmcid">PMC8440763</pub-id><pub-id pub-id-type="pmid">34521836</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal" id="sbref24"><person-group person-group-type="author"><name name-style="western"><surname>Channappanavar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fehr</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wohlford-Lenane</surname><given-names>C.</given-names></name><name name-style="western"><surname>Abrahante</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Mack</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sompallae</surname><given-names>R.</given-names></name><name name-style="western"><surname>McCray</surname><given-names>P.B.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Meyerholz</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name></person-group><article-title>IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes</article-title><source>J. Clin. Invest</source><volume>130</volume><year>2019</year><fpage>3625</fpage><lpage>3639</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI126363</pub-id><pub-id pub-id-type="pmcid">PMC6715373</pub-id><pub-id pub-id-type="pmid">31355779</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal" id="sbref25"><person-group person-group-type="author"><name name-style="western"><surname>Channappanavar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fehr</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wohlford-Lenane</surname><given-names>C.</given-names></name><name name-style="western"><surname>Abrahante</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Mack</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sompallae</surname><given-names>R.</given-names></name><name name-style="western"><surname>McCray</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Meyerholz</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name></person-group><article-title>IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes</article-title><source>J. Clin. Investig.</source><volume>129</volume><year>2019</year><fpage>3625</fpage><lpage>3639</lpage><pub-id pub-id-type="pmid">31355779</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI126363</pub-id><pub-id pub-id-type="pmcid">PMC6715373</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal" id="sbref26"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Clinical and immunological features of severe and moderate coronavirus disease 2019</article-title><source>J. Clin. Invest</source><volume>130</volume><year>2020</year><fpage>2620</fpage><lpage>2629</lpage><pub-id pub-id-type="pmid">32217835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI137244</pub-id><pub-id pub-id-type="pmcid">PMC7190990</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal" id="sbref27"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Han</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2</article-title><source>Sci. Bull.</source><volume>67</volume><year>2022</year><fpage>1372</fpage><lpage>1387</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.scib.2022.05.018</pub-id><pub-id pub-id-type="pmcid">PMC9134758</pub-id><pub-id pub-id-type="pmid">35637645</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal" id="sbref28"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>G.</given-names></name></person-group><article-title>Kidney disease is associated with in-hospital death of patients with COVID-19</article-title><source>Kidney Int</source><volume>97</volume><year>2020</year><fpage>829</fpage><lpage>838</lpage><pub-id pub-id-type="pmid">32247631</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.kint.2020.03.005</pub-id><pub-id pub-id-type="pmcid">PMC7110296</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal" id="sbref29"><person-group person-group-type="author"><name name-style="western"><surname>Cho</surname><given-names>K.</given-names></name><name name-style="western"><surname>Keithly</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Kurgansky</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Madenci</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Gerlovin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Marucci-Wellman</surname><given-names>H.</given-names></name><name name-style="western"><surname>Doubleday</surname><given-names>A.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Park</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>Y.-L.</given-names></name><etal/></person-group><article-title>Early convalescent plasma therapy and mortality among US Veterans Hospitalized With Nonsevere COVID-19: an observational analysis emulating a target trial</article-title><source>J. Infect. Dis.</source><volume>224</volume><year>2021</year><fpage>967</fpage><lpage>975</lpage><pub-id pub-id-type="pmid">34153099</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiab330</pub-id><pub-id pub-id-type="pmcid">PMC8411382</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal" id="sbref30"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Linderman</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Moodie</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Czartoski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mantus</surname><given-names>G.</given-names></name><name name-style="western"><surname>Norwood</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nyhoff</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Edara</surname><given-names>V.V.</given-names></name><name name-style="western"><surname>Floyd</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells. Cell Reports</article-title><source>Medicine</source><year>2021</year><fpage>2</fpage><pub-id pub-id-type="pmid">34250512</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xcrm.2021.100354</pub-id><pub-id pub-id-type="pmcid">PMC8253687</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal" id="sbref31"><person-group person-group-type="author"><name name-style="western"><surname>Cooper</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Alder</surname><given-names>M.N.</given-names></name></person-group><article-title>The evolution of adaptive immune systems</article-title><source>Cell</source><volume>124</volume><year>2006</year><fpage>815</fpage><lpage>822</lpage><pub-id pub-id-type="pmid">16497590</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2006.02.001</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal" id="sbref32"><person-group person-group-type="author"><name name-style="western"><surname>Criner</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Mathews</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Rice</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Madduri</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bellam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jeanfreau</surname><given-names>R.</given-names></name><name name-style="western"><surname>Case</surname><given-names>A.H.</given-names></name><etal/></person-group><article-title>Anti-granulocyte&#8211;macrophage colony&#8211;stimulating factor monoclonal antibody gimsilumab for covid-19 pneumonia: a randomized, double-blind, placebo-controlled trial</article-title><source>Am. J. Respir. Crit. Care Med.</source><volume>205</volume><year>2022</year><fpage>1290</fpage><lpage>1299</lpage><pub-id pub-id-type="pmid">35290169</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.202108-1859OC</pub-id><pub-id pub-id-type="pmcid">PMC9873114</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal" id="sbref33"><person-group person-group-type="author"><name name-style="western"><surname>Curtis</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sparrow</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ghebreyesus</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Netea</surname><given-names>M.G.</given-names></name></person-group><article-title>Considering BCG vaccination to reduce the impact of COVID-19</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>1545</fpage><lpage>1546</lpage><pub-id pub-id-type="pmid">32359402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31025-4</pub-id><pub-id pub-id-type="pmcid">PMC7252177</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal" id="sbref34"><person-group person-group-type="author"><name name-style="western"><surname>da Silva Antunes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pallikkuth</surname><given-names>S.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dawen Yu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mateus</surname><given-names>J.</given-names></name><name name-style="western"><surname>Quiambao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rawlings</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Stadlbauer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Differential T-cell reactivity to endemic coronaviruses and SARS-CoV-2 in community and health care workers</article-title><source>J. Infect. Dis.</source><volume>224</volume><year>2021</year><fpage>70</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">33822097</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiab176</pub-id><pub-id pub-id-type="pmcid">PMC8083569</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal" id="sbref35"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>McCorkell</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Topol</surname><given-names>E.J.</given-names></name></person-group><article-title>Long COVID: major findings, mechanisms and recommendations</article-title><source>Nat. Rev. Microbiol.</source><year>2023</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41579-022-00846-2</pub-id><pub-id pub-id-type="pmcid">PMC9839201</pub-id><pub-id pub-id-type="pmid">36639608</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal" id="sbref36"><person-group person-group-type="author"><name name-style="western"><surname>De Biasi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Meschiari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gibellini</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bellinazzi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Borella</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fidanza</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gozzi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Iannone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lo Tartaro</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mattioli</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia</article-title><source>Nat. Commun.</source><year>2020</year><fpage>11</fpage><pub-id pub-id-type="pmid">32632085</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-17292-4</pub-id><pub-id pub-id-type="pmcid">PMC7338513</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal" id="sbref37"><person-group person-group-type="author"><name name-style="western"><surname>De Leeuw</surname><given-names>E.</given-names></name><name name-style="western"><surname>Van Damme</surname><given-names>K.F.A.</given-names></name><name name-style="western"><surname>Declercq</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bosteels</surname><given-names>C.</given-names></name><name name-style="western"><surname>Maes</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tavernier</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Detalle</surname><given-names>L.</given-names></name><name name-style="western"><surname>Smart</surname><given-names>T.</given-names></name><name name-style="western"><surname>Glatt</surname><given-names>S.</given-names></name><name name-style="western"><surname>Debeuf</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial</article-title><source>Respir. Res.</source><year>2022</year><fpage>23</fpage><pub-id pub-id-type="pmid">35945604</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12931-022-02126-2</pub-id><pub-id pub-id-type="pmcid">PMC9361275</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal" id="sbref38"><person-group person-group-type="author"><name name-style="western"><surname>Diao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ning</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)</article-title><source>Front Immunol.</source><volume>11</volume><year>2020</year><fpage>827</fpage><pub-id pub-id-type="pmid">32425950</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.00827</pub-id><pub-id pub-id-type="pmcid">PMC7205903</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal" id="sbref39"><person-group person-group-type="author"><name name-style="western"><surname>Diao</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ning</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Reduction and Functional Exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)</article-title><source>Front. Immunol.</source><year>2020</year><fpage>11</fpage><pub-id pub-id-type="pmid">32425950</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.00827</pub-id><pub-id pub-id-type="pmcid">PMC7205903</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal" id="sbref40"><person-group person-group-type="author"><name name-style="western"><surname>Dinarello</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>A.</given-names></name><name name-style="western"><surname>van der Meer</surname><given-names>J.W.</given-names></name></person-group><article-title>Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases</article-title><source>Nat. Rev. Drug Disco</source><volume>11</volume><year>2012</year><fpage>633</fpage><lpage>652</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd3800</pub-id><pub-id pub-id-type="pmcid">PMC3644509</pub-id><pub-id pub-id-type="pmid">22850787</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal" id="sbref41"><person-group person-group-type="author"><name name-style="western"><surname>Duan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Effectiveness of convalescent plasma therapy in severe COVID-19 patients</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>117</volume><year>2020</year><fpage>9490</fpage><lpage>9496</lpage><pub-id pub-id-type="pmid">32253318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2004168117</pub-id><pub-id pub-id-type="pmcid">PMC7196837</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal" id="sbref42"><person-group person-group-type="author"><name name-style="western"><surname>Duggan</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Buechler</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Olson</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Hohl</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Hamerman</surname><given-names>J.A.</given-names></name></person-group><article-title>BCAP inhibits proliferation and differentiation of myeloid progenitors in the steady state and during demand situations</article-title><source>Blood</source><volume>129</volume><year>2017</year><fpage>1503</fpage><lpage>1513</lpage><pub-id pub-id-type="pmid">28087538</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2016-06-719823</pub-id><pub-id pub-id-type="pmcid">PMC5356451</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal" id="sbref43"><person-group person-group-type="author"><name name-style="western"><surname>Enard</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gwennap</surname><given-names>C.</given-names></name><name name-style="western"><surname>Petrov</surname><given-names>D.A.</given-names></name></person-group><article-title>Viruses are a dominant driver of protein adaptation in mammals</article-title><source>Elife</source><year>2016</year><fpage>5</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.12469</pub-id><pub-id pub-id-type="pmcid">PMC4869911</pub-id><pub-id pub-id-type="pmid">27187613</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal" id="sbref44"><person-group person-group-type="author"><name name-style="western"><surname>Faustman</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hostetter</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Aristarkhova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Shpilsky</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wolfe</surname><given-names>G.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dias</surname><given-names>H.F.</given-names></name><etal/></person-group><article-title>Multiple BCG vaccinations for the prevention of COVID-19 and other infectious diseases in type 1 diabetes. Cell Reports</article-title><source>Medicine</source><year>2022</year><fpage>3</fpage><pub-id pub-id-type="pmid">36027906</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xcrm.2022.100728</pub-id><pub-id pub-id-type="pmcid">PMC9376308</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal" id="sbref45"><person-group person-group-type="author"><name name-style="western"><surname>Feldmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maini</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Woody</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Holgate</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Winter</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rowland</surname><given-names>M.</given-names></name><name name-style="western"><surname>Richards</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hussell</surname><given-names>T.</given-names></name></person-group><article-title>Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>1407</fpage><lpage>1409</lpage><pub-id pub-id-type="pmid">32278362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30858-8</pub-id><pub-id pub-id-type="pmcid">PMC7158940</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal" id="sbref46"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>F.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>X.</given-names></name></person-group><article-title>Potential genes associated with COVID-19 and comorbidity</article-title><source>Int. J. Med. Sci.</source><volume>19</volume><year>2022</year><fpage>402</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">35165525</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/ijms.67815</pub-id><pub-id pub-id-type="pmcid">PMC8795808</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal" id="sbref47"><person-group person-group-type="author"><name name-style="western"><surname>Fischer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>P.</given-names></name><name name-style="western"><surname>Voelkl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Meidenbauer</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ammer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Edinger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gottfried</surname><given-names>E.</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rothe</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hoves</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Inhibitory effect of tumor cell-derived lactic acid on human T cells</article-title><source>Blood</source><volume>109</volume><year>2007</year><fpage>3812</fpage><lpage>3819</lpage><pub-id pub-id-type="pmid">17255361</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2006-07-035972</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal" id="sbref48"><person-group person-group-type="author"><name name-style="western"><surname>Gan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name></person-group><article-title>Does potential antibody-dependent enhancement occur during SARS-CoV-2 infection after natural infection or vaccination? A meta-analysis</article-title><source>BMC Infect. Dis.</source><year>2022</year><fpage>22</fpage><pub-id pub-id-type="pmid">36123623</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12879-022-07735-2</pub-id><pub-id pub-id-type="pmcid">PMC9483537</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal" id="sbref49"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Rapid development of an inactivated vaccine candidate for SARS-CoV-2</article-title><source>Science</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abc1932</pub-id><pub-id pub-id-type="pmcid">PMC7202686</pub-id><pub-id pub-id-type="pmid">32376603</pub-id></element-citation></ref><ref id="bib55"><mixed-citation publication-type="other" id="othref0030">Gao, T., Hu, M., Zhang, X., Li, H., Zhu, L., Liu, H., Dong, Q., Zhang, Z., Wang, Z., Hu, Y.<italic toggle="yes">,</italic> et al. (2020b).</mixed-citation></ref><ref id="bib56"><mixed-citation publication-type="other" id="othref0035">Gong, J., Dong, H., Xia, S.Q., Huang, Y.Z., Wang, D., Zhao, Y., Liu, W., Tu, S., Zhang, M., Wang, Q.,&#160;Lu, F. , 2020.</mixed-citation></ref><ref id="bib57"><element-citation publication-type="journal" id="sbref50"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez-Perez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sanchez-Tarjuelo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shor</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nistal-Villan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ochando</surname><given-names>J.</given-names></name></person-group><article-title>The BCG vaccine for COVID-19: first verdict and future directions</article-title><source>Front. Immunol.</source><year>2021</year><fpage>12</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.632478</pub-id><pub-id pub-id-type="pmcid">PMC7982405</pub-id><pub-id pub-id-type="pmid">33763077</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal" id="sbref51"><person-group person-group-type="author"><name name-style="western"><surname>Goodridge</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kollmann</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>O.</given-names></name><name name-style="western"><surname>Netea</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Pollard</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>van Crevel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>C.B.</given-names></name></person-group><article-title>Harnessing the beneficial heterologous effects of vaccination</article-title><source>Nat. Rev. Immunol.</source><volume>16</volume><year>2016</year><fpage>392</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">27157064</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri.2016.43</pub-id><pub-id pub-id-type="pmcid">PMC4931283</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal" id="sbref52"><person-group person-group-type="author"><name name-style="western"><surname>Gralinski</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Sheahan</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Menachery</surname><given-names>V.D.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Leist</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Whitmore</surname><given-names>A.</given-names></name><name name-style="western"><surname>Heise</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R.S.</given-names></name></person-group><article-title>Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis</article-title><source>mBio</source><year>2018</year><fpage>9</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mBio.01753-18</pub-id><pub-id pub-id-type="pmcid">PMC6178621</pub-id><pub-id pub-id-type="pmid">30301856</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal" id="sbref53"><person-group person-group-type="author"><name name-style="western"><surname>Grifoni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Weiskopf</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Mateus</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dan</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Moderbacher</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Rawlings</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Sutherland</surname><given-names>A.</given-names></name><name name-style="western"><surname>Premkumar</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jadi</surname><given-names>R.S.</given-names></name><etal/></person-group><article-title>Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals</article-title><source>Cell</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.05.015</pub-id><pub-id pub-id-type="pmcid">PMC7237901</pub-id><pub-id pub-id-type="pmid">32473127</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal" id="sbref54"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Multiple organ infection and the pathogenesis of SARS</article-title><source>J. Exp. Med</source><volume>202</volume><year>2005</year><fpage>415</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">16043521</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20050828</pub-id><pub-id pub-id-type="pmcid">PMC2213088</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal" id="sbref55"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>D.</given-names></name></person-group><article-title>Targeting TNF-&#945; for COVID-19: recent advanced and controversies</article-title><source>Front. Public Health</source><year>2022</year><fpage>10</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fpubh.2022.833967</pub-id><pub-id pub-id-type="pmcid">PMC8873570</pub-id><pub-id pub-id-type="pmid">35223745</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal" id="sbref56"><person-group person-group-type="author"><name name-style="western"><surname>Haagmans</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gued&#225;n</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yap</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Young</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>R.</given-names></name><name name-style="western"><surname>Stoye</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>K.N.</given-names></name></person-group><article-title>SARS-CoV-2 ORF6 disrupts innate immune signalling by inhibiting cellular mRNA export</article-title><source>PLOS Pathog.</source><year>2022</year><fpage>18</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1010349</pub-id><pub-id pub-id-type="pmcid">PMC9451085</pub-id><pub-id pub-id-type="pmid">36007063</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal" id="sbref57"><person-group person-group-type="author"><name name-style="western"><surname>Hackbart</surname><given-names>M.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>S.C.</given-names></name></person-group><article-title>Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>117</volume><year>2020</year><fpage>8094</fpage><lpage>8103</lpage><pub-id pub-id-type="pmid">32198201</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1921485117</pub-id><pub-id pub-id-type="pmcid">PMC7149396</pub-id></element-citation></ref><ref id="bib65"><mixed-citation publication-type="other" id="othref0040">Hamiel, U., Kozer, E.,&#160;Youngster, I. , 2020. SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults. Jama.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.8189</pub-id><pub-id pub-id-type="pmcid">PMC7221856</pub-id><pub-id pub-id-type="pmid">32401274</pub-id></mixed-citation></ref><ref id="bib66"><element-citation publication-type="journal" id="sbref58"><person-group person-group-type="author"><name name-style="western"><surname>Hennekens</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Rane</surname><given-names>M.</given-names></name><name name-style="western"><surname>Solano</surname><given-names>J.</given-names></name><name name-style="western"><surname>Alter</surname><given-names>S.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Krishnaswamy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shih</surname><given-names>R.</given-names></name><name name-style="western"><surname>Maki</surname><given-names>D.</given-names></name><name name-style="western"><surname>DeMets</surname><given-names>D.L.</given-names></name></person-group><article-title>Updates on hydroxychloroquine in prevention and treatment of COVID-19. The</article-title><source>Am. J. Med.</source><volume>135</volume><year>2022</year><fpage>7</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">34437834</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjmed.2021.07.035</pub-id><pub-id pub-id-type="pmcid">PMC8381625</pub-id></element-citation></ref><ref id="bib67"><mixed-citation publication-type="other" id="othref0045">Henry, B.M., and Lippi, G. (2020). Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int Urol Nephrol.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11255-020-02451-9</pub-id><pub-id pub-id-type="pmcid">PMC7103107</pub-id><pub-id pub-id-type="pmid">32222883</pub-id></mixed-citation></ref><ref id="bib68"><element-citation publication-type="journal" id="sbref59"><person-group person-group-type="author"><name name-style="western"><surname>Hermine</surname><given-names>O.</given-names></name><name name-style="western"><surname>Mariette</surname><given-names>X.</given-names></name><name name-style="western"><surname>Porcher</surname><given-names>R.</given-names></name><name name-style="western"><surname>Djossou</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Arlet</surname><given-names>J.-B.</given-names></name><name name-style="western"><surname>Savale</surname><given-names>L.</given-names></name><name name-style="western"><surname>Diehl</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Georgin-Lavialle</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cadranel</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19</article-title><source>pneumonia: A Random Clin. Trial CORIMUNO-19 Study Group. eClinicalMedicine</source><year>2022</year><fpage>46</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2022.101362</pub-id><pub-id pub-id-type="pmcid">PMC8949640</pub-id><pub-id pub-id-type="pmid">35350097</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal" id="sbref60"><person-group person-group-type="author"><name name-style="western"><surname>Hirano</surname><given-names>T.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>M.</given-names></name></person-group><article-title>COVID-19: a new virus, but a familiar receptor and cytokine release syndrome</article-title><source>Immunity</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2020.04.003</pub-id><pub-id pub-id-type="pmcid">PMC7175868</pub-id><pub-id pub-id-type="pmid">32325025</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal" id="sbref61"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kleine-Weber</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kruger</surname><given-names>N.</given-names></name><name name-style="western"><surname>Herrler</surname><given-names>T.</given-names></name><name name-style="western"><surname>Erichsen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schiergens</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Herrler</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Nitsche</surname><given-names>A.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title><source>Cell</source><volume>181</volume><issue>271&#8211;280</issue><year>2020</year><object-id pub-id-type="publisher-id">e278</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.02.052</pub-id><pub-id pub-id-type="pmcid">PMC7102627</pub-id><pub-id pub-id-type="pmid">32142651</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal" id="sbref62"><person-group person-group-type="author"><name name-style="western"><surname>Honardoost</surname><given-names>M.</given-names></name><name name-style="western"><surname>Janani</surname><given-names>L.</given-names></name><name name-style="western"><surname>Aghili</surname><given-names>R.</given-names></name><name name-style="western"><surname>Emami</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Khamseh</surname><given-names>M.E.</given-names></name></person-group><article-title>The association between presence of comorbidities and COVID-19 severity: a systematic review and meta-analysis</article-title><source>Cerebrovasc. Dis.</source><volume>50</volume><year>2021</year><fpage>132</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">33530081</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000513288</pub-id><pub-id pub-id-type="pmcid">PMC7900456</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal" id="sbref63"><person-group person-group-type="author"><name name-style="western"><surname>Horowitz</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Kosmicki</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Damask</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>D.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>G.H.L.</given-names></name><name name-style="western"><surname>Justice</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>N.</given-names></name><name name-style="western"><surname>Coignet</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leader</surname><given-names>J.B.</given-names></name><etal/></person-group><article-title>Genome-wide analysis provides genetic evidence that ACE2 influences COVID-19 risk and yields risk scores associated with severe disease</article-title><source>Nat. Genet.</source><volume>54</volume><year>2022</year><fpage>382</fpage><lpage>392</lpage><pub-id pub-id-type="pmid">35241825</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-021-01006-7</pub-id><pub-id pub-id-type="pmcid">PMC9005345</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal" id="sbref64"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>C.</given-names></name></person-group><article-title>The severe acute respiratory syndrome coronavirus nucleocapsid inhibits type I interferon production by interfering with TRIM25-Mediated RIG-I ubiquitination</article-title><source>J. Virol.</source><year>2017</year><fpage>91</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02143-16</pub-id><pub-id pub-id-type="pmcid">PMC5375661</pub-id><pub-id pub-id-type="pmid">28148787</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal" id="sbref65"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">31986264</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30183-5</pub-id><pub-id pub-id-type="pmcid">PMC7159299</pub-id></element-citation></ref><ref id="bib75"><mixed-citation publication-type="other" id="othref0050">Iwasaki, A., Yang, Y.2020. The potential danger of suboptimal antibody responses in COVID-19. Nat Rev Immunol.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-020-0321-6</pub-id><pub-id pub-id-type="pmcid">PMC7187142</pub-id><pub-id pub-id-type="pmid">32317716</pub-id></mixed-citation></ref><ref id="bib76"><mixed-citation publication-type="other" id="othref0055">Jiang, H.-w, Li, Y., Zhang, H.-n, Wang, W., Men, D., Yang, X., Qi, H., Zhou, J., and Tao, S.-c (2020).</mixed-citation></ref><ref id="bib77"><element-citation publication-type="journal" id="sbref66"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Song</surname><given-names>N.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV</article-title><source>Emerg. Microbes Infect.</source><volume>7</volume><year>2018</year><fpage>77</fpage><pub-id pub-id-type="pmid">29691378</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41426-018-0063-8</pub-id><pub-id pub-id-type="pmcid">PMC5915580</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal" id="sbref67"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Han</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><etal/></person-group><article-title>DNA damage contributes to age&#8208;associated differences in SARS&#8208;CoV&#8208;2 infection</article-title><source>Aging Cell</source><year>2022</year><fpage>21</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acel.13729</pub-id><pub-id pub-id-type="pmcid">PMC9741512</pub-id><pub-id pub-id-type="pmid">36254583</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal" id="sbref68"><person-group person-group-type="author"><name name-style="western"><surname>Jin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>G.</given-names></name></person-group><article-title>Virology, Epidemiology, Pathogenesis, and Control of COVID-19</article-title><source>Viruses</source><year>2020</year><fpage>12</fpage><pub-id pub-id-type="pmid">32230900</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v12040372</pub-id><pub-id pub-id-type="pmcid">PMC7232198</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal" id="sbref69"><person-group person-group-type="author"><name name-style="western"><surname>Junqueira</surname><given-names>C.</given-names></name><name name-style="western"><surname>Crespo</surname><given-names>&#194;.</given-names></name><name name-style="western"><surname>Ranjbar</surname><given-names>S.</given-names></name><name name-style="western"><surname>de Lacerda</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Lewandrowski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ingber</surname><given-names>J.</given-names></name><name name-style="western"><surname>Parry</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ravid</surname><given-names>S.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schrimpf</surname><given-names>M.R.</given-names></name><etal/></person-group><article-title>Fc&#947;R-mediated SARS-CoV-2 infection of monocytes activates inflammation</article-title><source>Nature</source><volume>606</volume><year>2022</year><fpage>576</fpage><lpage>584</lpage><pub-id pub-id-type="pmid">35385861</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-022-04702-4</pub-id><pub-id pub-id-type="pmcid">PMC10071495</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal" id="sbref70"><person-group person-group-type="author"><name name-style="western"><surname>Kalil</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Tomashek</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Wolfe</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Ghazaryan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Marconi</surname><given-names>V.C.</given-names></name><name name-style="western"><surname>Ruiz-Palacios</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kline</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Baricitinib plus remdesivir for hospitalized adults with covid-19</article-title><source>N. Engl. J. Med.</source><volume>384</volume><year>2021</year><fpage>795</fpage><lpage>807</lpage><pub-id pub-id-type="pmid">33306283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2031994</pub-id><pub-id pub-id-type="pmcid">PMC7745180</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal" id="sbref71"><person-group person-group-type="author"><name name-style="western"><surname>Kikkert</surname><given-names>M.</given-names></name></person-group><article-title>Innate Immune Evasion by Human Respiratory RNA Viruses</article-title><source>J. Innate Immun.</source><volume>12</volume><year>2020</year><fpage>4</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">31610541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000503030</pub-id><pub-id pub-id-type="pmcid">PMC6959104</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal" id="sbref72"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>E.</given-names></name><name name-style="western"><surname>Erdos</surname><given-names>G.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kenniston</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Balmert</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Carey</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Raj</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Epperly</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Klimstra</surname><given-names>W.B.</given-names></name><name name-style="western"><surname>Haagmans</surname><given-names>B.L.</given-names></name><etal/></person-group><article-title>Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development</article-title><source>EBioMedicine</source><year>2020</year><fpage>55</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2020.102743</pub-id><pub-id pub-id-type="pmcid">PMC7128973</pub-id><pub-id pub-id-type="pmid">32249203</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal" id="sbref73"><person-group person-group-type="author"><name name-style="western"><surname>Kohler</surname><given-names>K.</given-names></name><name name-style="western"><surname>Conway Morris</surname><given-names>A.</given-names></name></person-group><article-title>GM-CSF targeting in COVID-19: an approach based on fragile foundations</article-title><source>Eur. Respir. J.</source><year>2023</year><fpage>61</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/13993003.02091-2022</pub-id><pub-id pub-id-type="pmcid">PMC9686318</pub-id><pub-id pub-id-type="pmid">36396141</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal" id="sbref74"><person-group person-group-type="author"><name name-style="western"><surname>Kusnadi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ram&#237;rez-Su&#225;stegui</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fajardo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chee</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Meckiff</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pelosi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Seumois</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ay</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vijayanand</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ottensmeier</surname><given-names>C.H.</given-names></name></person-group><article-title>Severely ill patients with COVID-19 display impaired exhaustion features in SARS-CoV-2&#8211;reactive CD8+ T cells. Science</article-title><source>Immunology</source><year>2021</year><fpage>6</fpage><pub-id pub-id-type="pmid">33478949</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciimmunol.abe4782</pub-id><pub-id pub-id-type="pmcid">PMC8101257</pub-id></element-citation></ref><ref id="bib86"><mixed-citation publication-type="other" id="othref0060">Lan, L., Xu, D., Ye, G., Xia, C., Wang, S., Li, Y., and Xu, H. (2020). Positive RT-PCR Test Results in Patients Recovered From COVID-19. JAMA.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.2783</pub-id><pub-id pub-id-type="pmcid">PMC7047852</pub-id><pub-id pub-id-type="pmid">32105304</pub-id></mixed-citation></ref><ref id="bib87"><element-citation publication-type="journal" id="sbref75"><person-group person-group-type="author"><name name-style="western"><surname>Lau</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Peiris</surname><given-names>J.S.M.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Jensenius</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>E.Y.T.</given-names></name><name name-style="western"><surname>Au</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Chow</surname><given-names>E.Y.</given-names></name><name name-style="western"><surname>Yung</surname><given-names>R.W.H.</given-names></name><name name-style="western"><surname>To</surname><given-names>Y.F.</given-names></name><etal/></person-group><article-title>Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection</article-title><source>J. Infect. Dis.</source><volume>191</volume><year>2005</year><fpage>1697</fpage><lpage>1704</lpage><pub-id pub-id-type="pmid">15838797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/429631</pub-id><pub-id pub-id-type="pmcid">PMC7199483</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal" id="sbref76"><person-group person-group-type="author"><name name-style="western"><surname>Lazarus</surname><given-names>R.</given-names></name><name name-style="western"><surname>Querton</surname><given-names>B.</given-names></name><name name-style="western"><surname>Corbic Ramljak</surname><given-names>I.</given-names></name><name name-style="western"><surname>Dewasthaly</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jaramillo</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Dubischar</surname><given-names>K.</given-names></name><name name-style="western"><surname>Krammer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Weisova</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hochreiter</surname><given-names>R.</given-names></name><name name-style="western"><surname>Eder-Lingelbach</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial</article-title><source>Lancet Infect. Dis.</source><volume>22</volume><year>2022</year><fpage>1716</fpage><lpage>1727</lpage><pub-id pub-id-type="pmid">36075233</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(22)00502-3</pub-id><pub-id pub-id-type="pmcid">PMC9444237</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal" id="sbref77"><person-group person-group-type="author"><name name-style="western"><surname>Le Bert</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Kunasegaran</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tham</surname><given-names>C.Y.L.</given-names></name><name name-style="western"><surname>Hafezi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chng</surname><given-names>M.H.Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Linster</surname><given-names>M.</given-names></name><etal/></person-group><article-title>SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls</article-title><source>Nature</source><volume>584</volume><year>2020</year><fpage>457</fpage><lpage>462</lpage><pub-id pub-id-type="pmid">32668444</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2550-z</pub-id></element-citation></ref><ref id="bib90"><mixed-citation publication-type="other" id="othref0065">Li, X., Geng, M., Peng, Y., Meng, L., and Lu, S. (2020). Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpha.2020.03.001</pub-id><pub-id pub-id-type="pmcid">PMC7104082</pub-id><pub-id pub-id-type="pmid">32282863</pub-id></mixed-citation></ref><ref id="bib91"><element-citation publication-type="journal" id="sbref78"><person-group person-group-type="author"><name name-style="western"><surname>Libraty</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>O'Neil</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Acosta</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Olveda</surname><given-names>R.M.</given-names></name></person-group><article-title>Human CD4(+) memory T-lymphocyte responses to SARS coronavirus infection</article-title><source>Virology</source><volume>368</volume><year>2007</year><fpage>317</fpage><lpage>321</lpage><pub-id pub-id-type="pmid">17692881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.virol.2007.07.015</pub-id><pub-id pub-id-type="pmcid">PMC2094716</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal" id="sbref79"><person-group person-group-type="author"><name name-style="western"><surname>Libster</surname><given-names>R.</given-names></name><name name-style="western"><surname>P&#233;rez Marc</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wappner</surname><given-names>D.</given-names></name><name name-style="western"><surname>Coviello</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bianchi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Braem</surname><given-names>V.</given-names></name><name name-style="western"><surname>Esteban</surname><given-names>I.</given-names></name><name name-style="western"><surname>Caballero</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>C.</given-names></name><name name-style="western"><surname>Berrueta</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults</article-title><source>N. Engl. J. Med.</source><volume>384</volume><year>2021</year><fpage>610</fpage><lpage>618</lpage><pub-id pub-id-type="pmid">33406353</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2033700</pub-id><pub-id pub-id-type="pmcid">PMC7793608</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal" id="sbref80"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Hwa</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Shieh</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Yen</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.J.</given-names></name><etal/></person-group><article-title>Antibody to severe acute respiratory syndrome (SARS)-associated coronavirus spike protein domain 2 cross-reacts with lung epithelial cells and causes cytotoxicity</article-title><source>Clin. Exp. Immunol.</source><volume>141</volume><year>2005</year><fpage>500</fpage><lpage>508</lpage><pub-id pub-id-type="pmid">16045740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2249.2005.02864.x</pub-id><pub-id pub-id-type="pmcid">PMC1809466</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal" id="sbref81"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Muruato</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Periasamy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kurhade</surname><given-names>C.</given-names></name><name name-style="western"><surname>Plante</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Bopp</surname><given-names>N.E.</given-names></name><etal/></person-group><article-title>A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions. Nature</article-title><source>Communications</source><year>2022</year><fpage>13</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-31930-z</pub-id><pub-id pub-id-type="pmcid">PMC9326133</pub-id><pub-id pub-id-type="pmid">35896528</pub-id></element-citation></ref><ref id="bib95"><mixed-citation publication-type="other" id="othref0070">Lokugamage, K.G., Hage, A., Schindewolf, C., Rajsbaum, R.,&#160;Menachery, V.D. 2020.</mixed-citation></ref><ref id="bib96"><mixed-citation publication-type="other" id="othref0075">Long, Q.X., Liu, B.Z., Deng, H.J., Wu, G.C., Deng, K., Chen, Y.K., Liao, P., Qiu, J.F., Lin, Y., Cai, X.F.<italic toggle="yes">,</italic> et al. 2020. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-0897-1</pub-id><pub-id pub-id-type="pmid">32350462</pub-id></mixed-citation></ref><ref id="bib97"><mixed-citation publication-type="other" id="othref0080">Lukassen, S., Chua, R.L., Trefzer, T., Kahn, N.C., Schneider, M.A., Muley, T., Winter, H., Meister, M., Veith, C., Boots, A.W.<italic toggle="yes">,</italic> et al. 2020.<pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/embj.20105114</pub-id><pub-id pub-id-type="pmcid">PMC7232010</pub-id><pub-id pub-id-type="pmid">32246845</pub-id></mixed-citation></ref><ref id="bib98"><element-citation publication-type="journal" id="sbref82"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jing</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name></person-group><article-title>Global Percentage of Asymptomatic SARS-CoV-2 Infections Among the Tested Population and Individuals With Confirmed COVID-19 Diagnosis</article-title><source>JAMA Netw. Open</source><year>2021</year><fpage>4</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamanetworkopen.2021.37257</pub-id><pub-id pub-id-type="pmcid">PMC8672238</pub-id><pub-id pub-id-type="pmid">34905008</pub-id></element-citation></ref><ref id="bib99"><mixed-citation publication-type="other" id="othref0085">Magro, C., Mulvey, J.J., Berlin, D., Nuovo, G., Salvatore, S., Harp, J., Baxter-Stoltzfus, A.,&#160;Laurence, J.2020. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trsl.2020.04.007</pub-id><pub-id pub-id-type="pmcid">PMC7158248</pub-id><pub-id pub-id-type="pmid">32299776</pub-id></mixed-citation></ref><ref id="bib100"><element-citation publication-type="journal" id="sbref83"><person-group person-group-type="author"><name name-style="western"><surname>Malik</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mir</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shinde</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bender</surname><given-names>O.</given-names></name><name name-style="western"><surname>Alshammari</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ansari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Anwar</surname><given-names>S.</given-names></name></person-group><article-title>The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges</article-title><source>J. Infect. Public Health</source><volume>15</volume><year>2022</year><fpage>228</fpage><lpage>240</lpage><pub-id pub-id-type="pmid">35042059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jiph.2021.12.014</pub-id><pub-id pub-id-type="pmcid">PMC8730674</pub-id></element-citation></ref><ref id="bib101"><mixed-citation publication-type="other" id="othref0090">Manry, J., Bastard, P., Gervais, A., Le Voyer, T., Rosain, J., Philippot, Q., Michailidis, E., Hoffmann, H.-H., Eto, S., Garcia-Prat, M., et al. 2022. The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proceedings of the National Academy of Sciences 119.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2200413119</pub-id><pub-id pub-id-type="pmcid">PMC9173764</pub-id><pub-id pub-id-type="pmid">35576468</pub-id></mixed-citation></ref><ref id="bib102"><element-citation publication-type="journal" id="sbref84"><person-group person-group-type="author"><name name-style="western"><surname>Mantlo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bukreyeva</surname><given-names>N.</given-names></name><name name-style="western"><surname>Maruyama</surname><given-names>J.</given-names></name><name name-style="western"><surname>Paessler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name></person-group><article-title>Antiviral activities of type I interferons to SARS-CoV-2 infection</article-title><source>Antivir. Res</source><volume>179</volume><year>2020</year><object-id pub-id-type="publisher-id">104811</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.antiviral.2020.104811</pub-id><pub-id pub-id-type="pmcid">PMC7188648</pub-id><pub-id pub-id-type="pmid">32360182</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal" id="sbref85"><person-group person-group-type="author"><name name-style="western"><surname>Markiewski</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Lambris</surname><given-names>J.D.</given-names></name></person-group><article-title>The role of complement in inflammatory diseases from behind the scenes into the spotlight</article-title><source>Am. J. Pathol.</source><volume>171</volume><year>2007</year><fpage>715</fpage><lpage>727</lpage><pub-id pub-id-type="pmid">17640961</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2353/ajpath.2007.070166</pub-id><pub-id pub-id-type="pmcid">PMC1959484</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal" id="sbref86"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>F.</given-names></name></person-group><article-title>A rational design of a multi-epitope vaccine against SARS-CoV-2 which accounts for the glycan shield of the spike glycoprotein</article-title><source>J. Biomol. Struct. Dyn.</source><volume>40</volume><year>2021</year><fpage>7099</fpage><lpage>7113</lpage><pub-id pub-id-type="pmid">33715598</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/07391102.2021.1894986</pub-id><pub-id pub-id-type="pmcid">PMC9003619</pub-id></element-citation></ref><ref id="bib105"><mixed-citation publication-type="other" id="othref0095">McGonagle, D., O'Donnell, J.S., Sharif, K., Emery, P.,&#160;Bridgewood, C.2020. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. The Lancet Rheumatology.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2665-9913(20)30121-1</pub-id><pub-id pub-id-type="pmcid">PMC7252093</pub-id><pub-id pub-id-type="pmid">32835247</pub-id></mixed-citation></ref><ref id="bib106"><element-citation publication-type="journal" id="sbref87"><person-group person-group-type="author"><name name-style="western"><surname>McMahan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mercado</surname><given-names>N.B.</given-names></name><name name-style="western"><surname>Loos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tostanoski</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Chandrashekar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peter</surname><given-names>L.</given-names></name><name name-style="western"><surname>Atyeo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Correlates of protection against SARS-CoV-2 in rhesus macaques</article-title><source>Nature</source><volume>590</volume><year>2020</year><fpage>630</fpage><lpage>634</lpage><pub-id pub-id-type="pmid">33276369</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-03041-6</pub-id><pub-id pub-id-type="pmcid">PMC7906955</pub-id></element-citation></ref><ref id="bib107"><mixed-citation publication-type="other" id="othref0100">Miller, A.R., Mac &amp; Fasciglione, Kimberly &amp; Roumenova, Violeta &amp; Li, Yan &amp; Otazu, Gonzalo. 2020. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. medRxiv preprint.</mixed-citation></ref><ref id="bib108"><element-citation publication-type="journal" id="sbref88"><person-group person-group-type="author"><name name-style="western"><surname>Minozzi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bonovas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lytras</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pecoraro</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Lorenzo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bastiampillai</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Gabrielli</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Lonati</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Moja</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cinquini</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis</article-title><source>Expert Opin. Drug Saf.</source><volume>15</volume><year>2016</year><fpage>11</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">27924643</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14740338.2016.1240783</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal" id="sbref89"><person-group person-group-type="author"><name name-style="western"><surname>Miyamoto</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Itoh</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sakai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Koido</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hata</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.-X.</given-names></name><name name-style="western"><surname>Otani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moriishi</surname><given-names>K.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 ORF6 disrupts nucleocytoplasmic trafficking to advance viral replication. Communications</article-title><source>Biology</source><year>2022</year><fpage>5</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s42003-022-03427-4</pub-id><pub-id pub-id-type="pmcid">PMC9120032</pub-id><pub-id pub-id-type="pmid">35590097</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal" id="sbref90"><person-group person-group-type="author"><name name-style="western"><surname>Mu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Han</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Neutralizing antibodies from the rare convalescent donors elicited antibody-dependent enhancement of SARS-CoV-2 variants infection</article-title><source>Front. Med.</source><year>2022</year><fpage>9</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2022.952697</pub-id><pub-id pub-id-type="pmcid">PMC9627283</pub-id><pub-id pub-id-type="pmid">36341247</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal" id="sbref91"><person-group person-group-type="author"><name name-style="western"><surname>Muecksch</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gaebler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ben Tanfous</surname><given-names>T.</given-names></name><name name-style="western"><surname>DaSilva</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bednarski</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>V.</given-names></name><name name-style="western"><surname>Zong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost</article-title><source>Nature</source><volume>607</volume><year>2022</year><fpage>128</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">35447027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-022-04778-y</pub-id><pub-id pub-id-type="pmcid">PMC9259484</pub-id></element-citation></ref><ref id="bib112"><mixed-citation publication-type="other" id="othref0105">Muus, C., Luecken, M.D., Eraslan, G., Waghray, A., Heimberg, G., Sikkema, L., Kobayashi, Y., Vaishnav, E.D., Subramanian, A., Smilie, C.<italic toggle="yes">,</italic> et al. 2020.</mixed-citation></ref><ref id="bib113"><element-citation publication-type="journal" id="sbref92"><person-group person-group-type="author"><name name-style="western"><surname>Nelde</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bilich</surname><given-names>T.</given-names></name><name name-style="western"><surname>Heitmann</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Maringer</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Salih</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Roerden</surname><given-names>M.</given-names></name><name name-style="western"><surname>L&#252;bke</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rieth</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wacker</surname><given-names>M.</given-names></name><etal/></person-group><article-title>SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition</article-title><source>Nat. Immunol.</source><volume>22</volume><year>2020</year><fpage>74</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">32999467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41590-020-00808-x</pub-id></element-citation></ref><ref id="bib114"><mixed-citation publication-type="other" id="othref0110">Netea, M.G., Dom&#237;nguez-Andr&#233;s, J., Barreiro, L.B., Chavakis, T., Divangahi, M., Fuchs, E., Joosten, L.A.B., van der Meer, J.W.M., Mhlanga, M.M., Mulder, W.J.M.<italic toggle="yes">,</italic> et al. (2020). Defining trained immunity and its role in health and disease. Nature Reviews Immunology.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-020-0285-6</pub-id><pub-id pub-id-type="pmcid">PMC7186935</pub-id><pub-id pub-id-type="pmid">32132681</pub-id></mixed-citation></ref><ref id="bib115"><element-citation publication-type="journal" id="sbref93"><person-group person-group-type="author"><name name-style="western"><surname>Ng</surname><given-names>O.W.</given-names></name><name name-style="western"><surname>Chia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Jadi</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Leong</surname><given-names>H.N.</given-names></name><name name-style="western"><surname>Bertoletti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y.J.</given-names></name></person-group><article-title>Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection</article-title><source>Vaccine</source><volume>34</volume><year>2016</year><fpage>2008</fpage><lpage>2014</lpage><pub-id pub-id-type="pmid">26954467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2016.02.063</pub-id><pub-id pub-id-type="pmcid">PMC7115611</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal" id="sbref94"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bass</surname><given-names>D.</given-names></name><name name-style="western"><surname>Beishuizen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bocca Ruiz</surname><given-names>X.</given-names></name><name name-style="western"><surname>Boughanmi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cahn</surname><given-names>A.</given-names></name><name name-style="western"><surname>Colombo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Criner</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Davy</surname><given-names>K.</given-names></name><name name-style="western"><surname>de-Miguel-D&#237;ez</surname><given-names>J.</given-names></name><etal/></person-group><article-title>A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR)</article-title><source>Eur. Respir. J.</source><year>2023</year><fpage>61</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/13993003.01870-2021</pub-id><pub-id pub-id-type="pmcid">PMC9558428</pub-id><pub-id pub-id-type="pmid">36229048</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal" id="sbref95"><person-group person-group-type="author"><name name-style="western"><surname>Pedersen</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>Y.C.</given-names></name></person-group><article-title>SARS-CoV-2: a storm is raging</article-title><source>J. Clin. Invest</source><volume>130</volume><year>2020</year><fpage>2202</fpage><lpage>2205</lpage><pub-id pub-id-type="pmid">32217834</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI137647</pub-id><pub-id pub-id-type="pmcid">PMC7190904</pub-id></element-citation></ref><ref id="bib118"><mixed-citation publication-type="other" id="othref0115">Peeples, L.2020. News Feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine. Proceedings of the National Academy of Sciences 117, 8218&#8211;8221.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2005456117</pub-id><pub-id pub-id-type="pmcid">PMC7165470</pub-id><pub-id pub-id-type="pmid">32229574</pub-id></mixed-citation></ref><ref id="bib119"><element-citation publication-type="journal" id="sbref96"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mentzer</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dejnirattisai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Rostron</surname><given-names>T.</given-names></name><name name-style="western"><surname>Supasa</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19</article-title><source>Nat. Immunol.</source><volume>21</volume><year>2020</year><fpage>1336</fpage><lpage>1345</lpage><pub-id pub-id-type="pmid">32887977</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41590-020-0782-6</pub-id><pub-id pub-id-type="pmcid">PMC7611020</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal" id="sbref97"><person-group person-group-type="author"><name name-style="western"><surname>Perricone</surname><given-names>C.</given-names></name><name name-style="western"><surname>Triggianese</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bartoloni</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cafaro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bonifacio</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Bursi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Perricone</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gerli</surname><given-names>R.</given-names></name></person-group><article-title>The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19</article-title><source>J. Autoimmun.</source><year>2020</year><object-id pub-id-type="publisher-id">102468</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaut.2020.102468</pub-id><pub-id pub-id-type="pmcid">PMC7164894</pub-id><pub-id pub-id-type="pmid">32317220</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal" id="sbref98"><person-group person-group-type="author"><name name-style="western"><surname>Pietras</surname><given-names>E.M.</given-names></name></person-group><article-title>Inflammation: a key regulator of hematopoietic stem cell fate in health and disease</article-title><source>Blood</source><volume>130</volume><year>2017</year><fpage>1693</fpage><lpage>1698</lpage><pub-id pub-id-type="pmid">28874349</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2017-06-780882</pub-id><pub-id pub-id-type="pmcid">PMC5639485</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal" id="sbref99"><person-group person-group-type="author"><name name-style="western"><surname>Prompetchara</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ketloy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Palaga</surname><given-names>T.</given-names></name></person-group><article-title>Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic</article-title><source>Asian Pac. J. Allergy Immunol.</source><volume>38</volume><year>2020</year><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">32105090</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.12932/AP-200220-0772</pub-id></element-citation></ref><ref id="bib123"><mixed-citation publication-type="other" id="othref0120">Qamar et al., 2020.</mixed-citation></ref><ref id="bib124"><element-citation publication-type="journal" id="sbref100"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>D.S.</given-names></name></person-group><article-title>Dysregulation of immune response in patients with COVID-19 in Wuhan, China</article-title><source>Clin. Infect. Dis.</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciaa248</pub-id><pub-id pub-id-type="pmcid">PMC7108125</pub-id><pub-id pub-id-type="pmid">32161940</pub-id></element-citation></ref><ref id="bib125"><mixed-citation publication-type="other" id="othref0125">Redelman-Sidi, G. (2020). Could BCG be used to protect against COVID-19? Nature Reviews Urology.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41585-020-0325-9</pub-id><pub-id pub-id-type="pmcid">PMC7184546</pub-id><pub-id pub-id-type="pmid">32341531</pub-id></mixed-citation></ref><ref id="bib126"><element-citation publication-type="journal" id="sbref101"><person-group person-group-type="author"><name name-style="western"><surname>Reikine</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Modis</surname><given-names>Y.</given-names></name></person-group><article-title>Pattern Recognition and Signaling Mechanisms of RIG-I and MDA5</article-title><source>Front Immunol.</source><volume>5</volume><year>2014</year><fpage>342</fpage><pub-id pub-id-type="pmid">25101084</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2014.00342</pub-id><pub-id pub-id-type="pmcid">PMC4107945</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal" id="sbref102"><person-group person-group-type="author"><name name-style="western"><surname>Rha</surname><given-names>M.-S.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>E.-C.</given-names></name></person-group><article-title>Activation or exhaustion of CD8+ T cells in patients with COVID-19</article-title><source>Cell. Mol. Immunol.</source><volume>18</volume><year>2021</year><fpage>2325</fpage><lpage>2333</lpage><pub-id pub-id-type="pmid">34413488</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41423-021-00750-4</pub-id><pub-id pub-id-type="pmcid">PMC8374113</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal" id="sbref103"><person-group person-group-type="author"><name name-style="western"><surname>Richardson</surname><given-names>P.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>I.</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>C.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>D.</given-names></name><name name-style="western"><surname>Oechsle</surname><given-names>O.</given-names></name><name name-style="western"><surname>Phelan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stebbing</surname><given-names>J.</given-names></name></person-group><article-title>Baricitinib as potential treatment for 2019-nCoV acute respiratory disease</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>e30</fpage><lpage>e31</lpage><pub-id pub-id-type="pmid">32032529</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30304-4</pub-id><pub-id pub-id-type="pmcid">PMC7137985</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="journal" id="sbref104"><person-group person-group-type="author"><name name-style="western"><surname>Robson</surname><given-names>B.</given-names></name></person-group><article-title>COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles&#8217; heel conserved region to minimize probability of escape mutations and drug resistance</article-title><source>Comput. Biol. Med.</source><year>2020</year><fpage>121</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.compbiomed.2020.103749</pub-id><pub-id pub-id-type="pmcid">PMC7151553</pub-id><pub-id pub-id-type="pmid">32568687</pub-id></element-citation></ref><ref id="bib130"><element-citation publication-type="journal" id="sbref105"><person-group person-group-type="author"><name name-style="western"><surname>Rock</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Kono</surname><given-names>H.</given-names></name></person-group><article-title>The inflammatory response to cell death</article-title><source>Annu Rev. Pathol.</source><volume>3</volume><year>2008</year><fpage>99</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">18039143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev.pathmechdis.3.121806.151456</pub-id><pub-id pub-id-type="pmcid">PMC3094097</pub-id></element-citation></ref><ref id="bib131"><element-citation publication-type="journal" id="sbref106"><person-group person-group-type="author"><name name-style="western"><surname>Rojas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rodr&#237;guez</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Acosta-Ampudia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Monsalve</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.-Z.</given-names></name><name name-style="western"><surname>Ram&#237;rez-Santana</surname><given-names>C.</given-names></name><name name-style="western"><surname>Anaya</surname><given-names>J.-M.</given-names></name></person-group><article-title>Autoimmunity is a hallmark of post-COVID syndrome</article-title><source>J. Transl. Med.</source><year>2022</year><fpage>20</fpage><pub-id pub-id-type="pmid">35296346</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-022-03328-4</pub-id><pub-id pub-id-type="pmcid">PMC8924736</pub-id></element-citation></ref><ref id="bib132"><element-citation publication-type="journal" id="sbref107"><person-group person-group-type="author"><name name-style="western"><surname>Rothan</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Byrareddy</surname><given-names>S.N.</given-names></name></person-group><article-title>The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak</article-title><source>J. Autoimmun.</source><year>2020</year><object-id pub-id-type="publisher-id">102433</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaut.2020.102433</pub-id><pub-id pub-id-type="pmcid">PMC7127067</pub-id><pub-id pub-id-type="pmid">32113704</pub-id></element-citation></ref><ref id="bib133"><element-citation publication-type="journal" id="sbref108"><person-group person-group-type="author"><name name-style="western"><surname>Roy</surname><given-names>K.</given-names></name><name name-style="western"><surname>Agarwal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>R.</given-names></name><name name-style="western"><surname>Paul</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Purbey</surname><given-names>P.K.</given-names></name></person-group><article-title>COVID-19 and gut immunomodulation</article-title><source>World J. Gastroenterol.</source><volume>27</volume><year>2021</year><fpage>7925</fpage><lpage>7942</lpage><pub-id pub-id-type="pmid">35046621</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3748/wjg.v27.i46.7925</pub-id><pub-id pub-id-type="pmcid">PMC8678818</pub-id></element-citation></ref><ref id="bib134"><element-citation publication-type="journal" id="sbref109"><person-group person-group-type="author"><name name-style="western"><surname>Rubin</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Longo</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Baden</surname><given-names>L.R.</given-names></name></person-group><article-title>Interleukin-6 Receptor Inhibition in Covid-19 &#8212; cooling the Inflammatory Soup</article-title><source>N. Engl. J. Med.</source><volume>384</volume><year>2021</year><fpage>1564</fpage><lpage>1565</lpage><pub-id pub-id-type="pmid">33631064</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMe2103108</pub-id><pub-id pub-id-type="pmcid">PMC7944949</pub-id></element-citation></ref><ref id="bib135"><element-citation publication-type="journal" id="sbref110"><person-group person-group-type="author"><name name-style="western"><surname>Sakaguchi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wing</surname><given-names>K.</given-names></name><name name-style="western"><surname>Onishi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Prieto-Martin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>T.</given-names></name></person-group><article-title>Regulatory T cells: how do they suppress immune responses?</article-title><source>Int Immunol.</source><volume>21</volume><year>2009</year><fpage>1105</fpage><lpage>1111</lpage><pub-id pub-id-type="pmid">19737784</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/intimm/dxp095</pub-id></element-citation></ref><ref id="bib136"><element-citation publication-type="journal" id="sbref111"><person-group person-group-type="author"><name name-style="western"><surname>Saksena</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Reche</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Bonam</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Mancini</surname><given-names>N.</given-names></name></person-group><article-title>Editorial: Innate immune responses to SARS-CoV-2 in infected and vaccinated individuals</article-title><source>Front. Immunol.</source><year>2023</year><fpage>14</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2023.1141405</pub-id><pub-id pub-id-type="pmcid">PMC9945333</pub-id><pub-id pub-id-type="pmid">36845086</pub-id></element-citation></ref><ref id="bib137"><mixed-citation publication-type="other" id="othref0130">Salazar, E., Perez, K.K., Ashraf, M., Chen, J., Castillo, B., Christensen, P.A., Eubank, T., Bernard, D.W., Eagar, T.N., Long, S.W.<italic toggle="yes">,</italic> et al. 2020.</mixed-citation></ref><ref id="bib138"><element-citation publication-type="journal" id="sbref112"><person-group person-group-type="author"><name name-style="western"><surname>Salian</surname><given-names>V.S.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Vedell</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kandimalla</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Carmona Porquera</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Kalari</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Kandimalla</surname><given-names>K.K.</given-names></name></person-group><article-title>COVID-19 transmission, current treatment, and future therapeutic strategies</article-title><source>Mol. Pharm.</source><volume>18</volume><year>2021</year><fpage>754</fpage><lpage>771</lpage><pub-id pub-id-type="pmid">33464914</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.molpharmaceut.0c00608</pub-id></element-citation></ref><ref id="bib139"><element-citation publication-type="journal" id="sbref113"><person-group person-group-type="author"><name name-style="western"><surname>Sallard</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lescure</surname><given-names>F.X.</given-names></name><name name-style="western"><surname>Yazdanpanah</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mentre</surname><given-names>F.</given-names></name><name name-style="western"><surname>Peiffer-Smadja</surname><given-names>N.</given-names></name></person-group><article-title>Type 1 interferons as a potential treatment against COVID-19</article-title><source>Antivir. Res</source><volume>178</volume><year>2020</year><object-id pub-id-type="publisher-id">104791</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.antiviral.2020.104791</pub-id><pub-id pub-id-type="pmcid">PMC7138382</pub-id><pub-id pub-id-type="pmid">32275914</pub-id></element-citation></ref><ref id="bib140"><element-citation publication-type="journal" id="sbref114"><person-group person-group-type="author"><name name-style="western"><surname>Santesmasses</surname><given-names>D.</given-names></name><name name-style="western"><surname>Castro</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Zenin</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Shindyapina</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Gerashchenko</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kerepesi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yim</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Fedichev</surname><given-names>P.O.</given-names></name><name name-style="western"><surname>Gladyshev</surname><given-names>V.N.</given-names></name></person-group><article-title>COVID&#8208;19 is an emergent disease of aging</article-title><source>Aging Cell</source><year>2020</year><fpage>19</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/acel.13230</pub-id><pub-id pub-id-type="pmcid">PMC7576244</pub-id><pub-id pub-id-type="pmid">33006233</pub-id></element-citation></ref><ref id="bib141"><mixed-citation publication-type="other" id="othref0135">Sanyal and K. Paul (2021). Organoid Technology and the COVID Pandemic. In SARS-CoV-2 Origin and COVID-19 Pandemic Across the Globe.</mixed-citation></ref><ref id="bib142"><element-citation publication-type="journal" id="sbref115"><person-group person-group-type="author"><name name-style="western"><surname>Schmidt</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Varga</surname><given-names>S.M.</given-names></name></person-group><article-title>The CD8 T Cell Response to Respiratory Virus Infections</article-title><source>Front Immunol.</source><volume>9</volume><year>2018</year><fpage>678</fpage><pub-id pub-id-type="pmid">29686673</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2018.00678</pub-id><pub-id pub-id-type="pmcid">PMC5900024</pub-id></element-citation></ref><ref id="bib143"><mixed-citation publication-type="other" id="othref0140">Schuhenn, J., Meister, T.L., Todt, D., Bracht, T., Schork, K., Billaud, J.-N., Elsner, C., Heinen, N., Karakoese, Z., Haid, S.<italic toggle="yes">,</italic> et al. 2022. Differential interferon-&#945; subtype induced immune signatures are associated with suppression of SARS-CoV-2 infection. Proceedings of the National Academy of Sciences 119.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.2111600119</pub-id><pub-id pub-id-type="pmcid">PMC8872780</pub-id><pub-id pub-id-type="pmid">35131898</pub-id></mixed-citation></ref><ref id="bib144"><element-citation publication-type="journal" id="sbref116"><person-group person-group-type="author"><name name-style="western"><surname>Schultze</surname><given-names>A.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>MacKenna</surname><given-names>B.</given-names></name><name name-style="western"><surname>Morton</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Bhaskaran</surname><given-names>K.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Rentsch</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>E.</given-names></name><name name-style="western"><surname>Drysdale</surname><given-names>H.</given-names></name><name name-style="western"><surname>Croker</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform</article-title><source>Lancet Respir. Med.</source><volume>8</volume><year>2020</year><fpage>1106</fpage><lpage>1120</lpage><pub-id pub-id-type="pmid">32979987</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-2600(20)30415-X</pub-id><pub-id pub-id-type="pmcid">PMC7515601</pub-id></element-citation></ref><ref id="bib145"><element-citation publication-type="journal" id="sbref117"><person-group person-group-type="author"><name name-style="western"><surname>Sefil</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ulutas</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Dokuyucu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sumbul</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Yengil</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yagiz</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Yula</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ustun</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gokce</surname><given-names>C.</given-names></name></person-group><article-title>Investigation of neutrophil lymphocyte ratio and blood glucose regulation in patients with type 2 diabetes mellitus</article-title><source>J. Int Med Res</source><volume>42</volume><year>2014</year><fpage>581</fpage><lpage>588</lpage><pub-id pub-id-type="pmid">24567354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0300060513516944</pub-id></element-citation></ref><ref id="bib146"><element-citation publication-type="journal" id="sbref118"><person-group person-group-type="author"><name name-style="western"><surname>Sekine</surname><given-names>T.</given-names></name><name name-style="western"><surname>Perez-Potti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rivera-Ballesteros</surname><given-names>O.</given-names></name><name name-style="western"><surname>Str&#229;lin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gorin</surname><given-names>J.-B.</given-names></name><name name-style="western"><surname>Olsson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Llewellyn-Lacey</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kamal</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bogdanovic</surname><given-names>G.</given-names></name><name name-style="western"><surname>Muschiol</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19</article-title><source>Cell</source><volume>183</volume><issue>158&#8211;168</issue><year>2020</year><object-id pub-id-type="publisher-id">e114</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.08.017</pub-id><pub-id pub-id-type="pmcid">PMC7427556</pub-id><pub-id pub-id-type="pmid">32979941</pub-id></element-citation></ref><ref id="bib147"><element-citation publication-type="journal" id="sbref119"><person-group person-group-type="author"><name name-style="western"><surname>Shaked</surname><given-names>Y.</given-names></name></person-group><article-title>The pro-tumorigenic host response to cancer therapies</article-title><source>Nat. Rev. Cancer</source><volume>19</volume><year>2019</year><fpage>667</fpage><lpage>685</lpage><pub-id pub-id-type="pmid">31645711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41568-019-0209-6</pub-id></element-citation></ref><ref id="bib148"><element-citation publication-type="journal" id="sbref120"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>X.-R.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.-F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Min</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>R.-D.</given-names></name><etal/></person-group><article-title>ACE2-independent infection of T lymphocytes by SARS-CoV-2</article-title><source>Signal Transduct. Target. Ther.</source><year>2022</year><fpage>7</fpage><pub-id pub-id-type="pmid">35277473</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-022-00919-x</pub-id><pub-id pub-id-type="pmcid">PMC8914143</pub-id></element-citation></ref><ref id="bib149"><mixed-citation publication-type="other" id="othref0145">Sheridan, C.2020. Convalescent serum lines up as first-choice treatment for coronavirus. Nat Biotechnol.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41587-020-00011-1</pub-id><pub-id pub-id-type="pmid">32358594</pub-id></mixed-citation></ref><ref id="bib150"><element-citation publication-type="journal" id="sbref121"><person-group person-group-type="author"><name name-style="western"><surname>Siddiqi</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Mehra</surname><given-names>M.R.</given-names></name></person-group><article-title>COVID-19 illness in native and immunosuppressed states: a clinical&#8211;therapeutic staging proposal</article-title><source>J. Heart Lung Transplant.</source><volume>39</volume><year>2020</year><fpage>405</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">32362390</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.healun.2020.03.012</pub-id><pub-id pub-id-type="pmcid">PMC7118652</pub-id></element-citation></ref><ref id="bib151"><element-citation publication-type="journal" id="sbref122"><person-group person-group-type="author"><name name-style="western"><surname>Simonovich</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Pratx</surname><given-names>Burgos</given-names></name><name name-style="western"><surname>Scibona</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Beruto</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vallone</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>V&#225;zquez</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Savoy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Giunta</surname><given-names>N.</given-names></name><name name-style="western"><surname>P&#233;rez</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>S&#225;nchez</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>M.d.L</surname></name><etal/></person-group><article-title>A randomized trial of convalescent plasma in Covid-19 severe pneumonia</article-title><source>N. Engl. J. Med.</source><volume>384</volume><year>2021</year><fpage>619</fpage><lpage>629</lpage><pub-id pub-id-type="pmid">33232588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2031304</pub-id><pub-id pub-id-type="pmcid">PMC7722692</pub-id></element-citation></ref><ref id="bib152"><element-citation publication-type="journal" id="sbref123"><person-group person-group-type="author"><name name-style="western"><surname>Skendros</surname><given-names>P.</given-names></name><name name-style="western"><surname>Germanidis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mastellos</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Antoniadou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gavriilidis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kalopitas</surname><given-names>G.</given-names></name><name name-style="western"><surname>Samakidou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Liontos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chrysanthopoulou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ntinopoulou</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Complement C3 inhibition in severe COVID-19 using compstatin AMY-101</article-title><source>Sci. Adv.</source><year>2022</year><fpage>8</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.abo2341</pub-id><pub-id pub-id-type="pmcid">PMC9385148</pub-id><pub-id pub-id-type="pmid">35977025</pub-id></element-citation></ref><ref id="bib153"><element-citation publication-type="journal" id="sbref124"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>N.</given-names></name><name name-style="western"><surname>Poss&#233;m&#233;</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bondet</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sugrue</surname><given-names>J.</given-names></name><name name-style="western"><surname>Townsend</surname><given-names>L.</given-names></name><name name-style="western"><surname>Charbit</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rouilly</surname><given-names>V.</given-names></name><name name-style="western"><surname>Saint-Andr&#233;</surname><given-names>V.</given-names></name><name name-style="western"><surname>Dott</surname><given-names>T.</given-names></name><name name-style="western"><surname>Pozo</surname><given-names>A.R.</given-names></name><etal/></person-group><article-title>Defective activation and regulation of type I interferon immunity is associated with increasing COVID-19 severity. Nature</article-title><source>Communications</source><year>2022</year><fpage>13</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-022-34895-1</pub-id><pub-id pub-id-type="pmcid">PMC9700809</pub-id><pub-id pub-id-type="pmid">36434007</pub-id></element-citation></ref><ref id="bib154"><element-citation publication-type="journal" id="sbref125"><person-group person-group-type="author"><name name-style="western"><surname>Soltani-Zangbar</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Parhizkar</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ghaedi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tarbiat</surname><given-names>A.</given-names></name><name name-style="western"><surname>Motavalli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Alizadegan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aghebati-Maleki</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rostamzadeh</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yousefzadeh</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jadideslam</surname><given-names>G.</given-names></name><etal/></person-group><article-title>A comprehensive evaluation of the immune system response and type-I Interferon signaling pathway in hospitalized COVID-19 patients</article-title><source>Cell Commun. Signal.</source><year>2022</year><fpage>20</fpage><pub-id pub-id-type="pmid">35842705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12964-022-00903-6</pub-id><pub-id pub-id-type="pmcid">PMC9287826</pub-id></element-citation></ref><ref id="bib155"><mixed-citation publication-type="other" id="othref0150">Son, K., Jamil, R., Chowdhury, A., Mukherjee, M., Venegas, C., Miyasaki, K., Zhang, K., Patel, Z., Salter, B., Yuen, A.C.Y.<italic toggle="yes">,</italic> et al.&#160;, 2022. Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms. European Respiratory Journal.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/13993003.00970-2022</pub-id><pub-id pub-id-type="pmcid">PMC9515477</pub-id><pub-id pub-id-type="pmid">36137590</pub-id></mixed-citation></ref><ref id="bib156"><element-citation publication-type="journal" id="sbref126"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>A.T.W.</given-names></name><name name-style="western"><surname>Rocha</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mendrone-J&#250;nior</surname><given-names>A.</given-names></name><name name-style="western"><surname>Calado</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>De Santis</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Benites</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Costa-Lima</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vargas</surname><given-names>T.</given-names></name><name name-style="western"><surname>Marques</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Treatment of severe COVID-19 patients with either low- or high-volume of convalescent plasma versus standard of care: a multicenter Bayesian randomized open-label clinical trial (COOP-COVID-19-MCTI)</article-title><source>Lancet Reg. Health - Am.</source><year>2022</year><fpage>10</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lana.2022.100216</pub-id><pub-id pub-id-type="pmcid">PMC8923059</pub-id><pub-id pub-id-type="pmid">35308034</pub-id></element-citation></ref><ref id="bib157"><element-citation publication-type="journal" id="sbref127"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>J.-W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>F.-P.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W.-J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>X.-P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.-Y.</given-names></name><etal/></person-group><article-title>Immunological and inflammatory profiles in mild and severe cases of COVID-19. Nature</article-title><source>Communications</source><year>2020</year><fpage>11</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-17240-2</pub-id><pub-id pub-id-type="pmcid">PMC7343781</pub-id><pub-id pub-id-type="pmid">32641700</pub-id></element-citation></ref><ref id="bib158"><mixed-citation publication-type="other" id="othref0155">Srivastava, S., Verma, S., Kamthania, M., Kaur, R., Badyal, R.K., Saxena, A.K., Shin, H.-J., Kolbe, M.,&#160;Pandey, K.C.2020.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/19371</pub-id><pub-id pub-id-type="pmcid">PMC7370533</pub-id><pub-id pub-id-type="pmid">32776022</pub-id></mixed-citation></ref><ref id="bib159"><element-citation publication-type="journal" id="sbref128"><person-group person-group-type="author"><name name-style="western"><surname>Stoermer</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>T.E.</given-names></name></person-group><article-title>Complement and viral pathogenesis</article-title><source>Virology</source><volume>411</volume><year>2011</year><fpage>362</fpage><lpage>373</lpage><pub-id pub-id-type="pmid">21292294</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.virol.2010.12.045</pub-id><pub-id pub-id-type="pmcid">PMC3073741</pub-id></element-citation></ref><ref id="bib160"><element-citation publication-type="journal" id="sbref129"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Song</surname><given-names>H.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Inhibition of complement activation alleviates acute lung injury induced by highly pathogenic avian influenza H5N1 virus infection</article-title><source>Am. J. Respir. Cell Mol. Biol.</source><volume>49</volume><year>2013</year><fpage>221</fpage><lpage>230</lpage><pub-id pub-id-type="pmid">23526211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1165/rcmb.2012-0428OC</pub-id></element-citation></ref><ref id="bib161"><element-citation publication-type="journal" id="sbref130"><person-group person-group-type="author"><name name-style="western"><surname>Sungnak</surname><given-names>W.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Becavin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Berg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Queen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Litvinukova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Talavera-Lopez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Maatz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Reichart</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sampaziotis</surname><given-names>F.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes</article-title><source>Nat. Med</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-0868-6</pub-id><pub-id pub-id-type="pmcid">PMC8637938</pub-id><pub-id pub-id-type="pmid">32327758</pub-id></element-citation></ref><ref id="bib162"><element-citation publication-type="journal" id="sbref131"><person-group person-group-type="author"><name name-style="western"><surname>Takeuchi</surname><given-names>O.</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name></person-group><article-title>Innate immunity to virus infection</article-title><source>Immunol. Rev.</source><volume>227</volume><year>2009</year><fpage>75</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">19120477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-065X.2008.00737.x</pub-id><pub-id pub-id-type="pmcid">PMC5489343</pub-id></element-citation></ref><ref id="bib163"><element-citation publication-type="journal" id="sbref132"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Miao</surname><given-names>H.</given-names></name></person-group><article-title>Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study</article-title><source>Signal Transduct. Target Ther.</source><volume>5</volume><year>2020</year><fpage>33</fpage><pub-id pub-id-type="pmid">32296069</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-020-0148-4</pub-id><pub-id pub-id-type="pmcid">PMC7100419</pub-id></element-citation></ref><ref id="bib164"><element-citation publication-type="journal" id="sbref133"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Quan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xin</surname><given-names>Z.T.</given-names></name><name name-style="western"><surname>Wrammert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Richardus</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>W.C.</given-names></name></person-group><article-title>Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study</article-title><source>J. Immunol.</source><volume>186</volume><year>2011</year><fpage>7264</fpage><lpage>7268</lpage><pub-id pub-id-type="pmid">21576510</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.0903490</pub-id></element-citation></ref><ref id="bib165"><element-citation publication-type="journal" id="sbref134"><person-group person-group-type="author"><name name-style="western"><surname>Thevarajan</surname><given-names>I.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>T.H.O.</given-names></name><name name-style="western"><surname>Koutsakos</surname><given-names>M.</given-names></name><name name-style="western"><surname>Druce</surname><given-names>J.</given-names></name><name name-style="western"><surname>Caly</surname><given-names>L.</given-names></name><name name-style="western"><surname>van de Sandt</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>X.</given-names></name><name name-style="western"><surname>Nicholson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Catton</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cowie</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19</article-title><source>Nat. Med</source><volume>26</volume><year>2020</year><fpage>453</fpage><lpage>455</lpage><pub-id pub-id-type="pmid">32284614</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-0819-2</pub-id><pub-id pub-id-type="pmcid">PMC7095036</pub-id></element-citation></ref><ref id="bib166"><element-citation publication-type="journal" id="sbref135"><person-group person-group-type="author"><name name-style="western"><surname>Thorne</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Reuschl</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Zuliani&#8208;Alvarez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Whelan</surname><given-names>M.V.X.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Noursadeghi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jolly</surname><given-names>C.</given-names></name><name name-style="western"><surname>Towers</surname><given-names>G.J.</given-names></name></person-group><article-title>SARS&#8208;CoV&#8208;2 sensing by RIG&#8208;I and MDA5 links epithelial infection to macrophage inflammation. The</article-title><source>EMBO J.</source><year>2021</year><fpage>40</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/embj.2021107826</pub-id><pub-id pub-id-type="pmcid">PMC8209947</pub-id><pub-id pub-id-type="pmid">34101213</pub-id></element-citation></ref><ref id="bib167"><element-citation publication-type="journal" id="sbref136"><person-group person-group-type="author"><name name-style="western"><surname>Thurman</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Yapa</surname><given-names>R.</given-names></name></person-group><article-title>Complement Therapeutics in Autoimmune Disease</article-title><source>Front Immunol.</source><volume>10</volume><year>2019</year><fpage>672</fpage><pub-id pub-id-type="pmid">31001274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.00672</pub-id><pub-id pub-id-type="pmcid">PMC6456694</pub-id></element-citation></ref><ref id="bib168"><element-citation publication-type="journal" id="sbref137"><person-group person-group-type="author"><name name-style="western"><surname>Upton</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>van Wijk</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Mockeliunas</surname><given-names>L.</given-names></name><name name-style="western"><surname>Simonsson</surname><given-names>U.S.H.</given-names></name><name name-style="western"><surname>McHarry</surname><given-names>K.</given-names></name><name name-style="western"><surname>van den Hoogen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>C.</given-names></name><name name-style="western"><surname>von Delft</surname><given-names>A.</given-names></name><name name-style="western"><surname>van der Westhuizen</surname><given-names>H.-M.</given-names></name><name name-style="western"><surname>van Crevel</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled</article-title><source>phase 3 Trial eClinicalMedicine</source><year>2022</year><fpage>48</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.eclinm.2022.101414</pub-id><pub-id pub-id-type="pmcid">PMC9098089</pub-id><pub-id pub-id-type="pmid">35582122</pub-id></element-citation></ref><ref id="bib169"><element-citation publication-type="journal" id="sbref138"><person-group person-group-type="author"><name name-style="western"><surname>van de Veerdonk</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>Netea</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>van Deuren</surname><given-names>M.</given-names></name><name name-style="western"><surname>van der Meer</surname><given-names>J.W.M.</given-names></name><name name-style="western"><surname>de Mast</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Br&#252;ggemann</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>van der Hoeven</surname><given-names>H.</given-names></name></person-group><article-title>Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome</article-title><source>eLife</source><year>2020</year><fpage>9</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.7554/eLife.57555</pub-id><pub-id pub-id-type="pmcid">PMC7213974</pub-id><pub-id pub-id-type="pmid">32338605</pub-id></element-citation></ref><ref id="bib170"><element-citation publication-type="journal" id="sbref139"><person-group person-group-type="author"><name name-style="western"><surname>Waltz</surname><given-names>E.</given-names></name></person-group><article-title>China and India approve nasal COVID vaccines &#8212; are they a game changer?</article-title><source>Nature</source><volume>609</volume><year>2022</year><comment>450-450.</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41586-022-02851-0</pub-id><pub-id pub-id-type="pmid">36071228</pub-id></element-citation></ref><ref id="bib171"><mixed-citation publication-type="other" id="othref0160">Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y.<italic toggle="yes">,</italic> et al. (2020). Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.1585</pub-id><pub-id pub-id-type="pmcid">PMC7042881</pub-id><pub-id pub-id-type="pmid">32031570</pub-id></mixed-citation></ref><ref id="bib172"><element-citation publication-type="journal" id="sbref140"><person-group person-group-type="author"><name name-style="western"><surname>Wertheim</surname><given-names>J.O.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Peiris</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Kosakovsky Pond</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Poon</surname><given-names>L.L.</given-names></name></person-group><article-title>A case for the ancient origin of coronaviruses</article-title><source>J. Virol.</source><volume>87</volume><year>2013</year><fpage>7039</fpage><lpage>7045</lpage><pub-id pub-id-type="pmid">23596293</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.03273-12</pub-id><pub-id pub-id-type="pmcid">PMC3676139</pub-id></element-citation></ref><ref id="bib173"><element-citation publication-type="journal" id="sbref141"><person-group person-group-type="author"><name name-style="western"><surname>Wolfel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Corman</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Guggemos</surname><given-names>W.</given-names></name><name name-style="western"><surname>Seilmaier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zange</surname><given-names>S.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Niemeyer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Vollmar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rothe</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Virological assessment of hospitalized patients with COVID-2019</article-title><source>Nature</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2196-x</pub-id><pub-id pub-id-type="pmid">32235945</pub-id></element-citation></ref><ref id="bib174"><mixed-citation publication-type="other" id="othref0165">Wu, F., Wang, A., Liu, M., Wang, Q., Chen, J., Xia, S., Ling, Y., Zhang, Y., Xun, J., Lu, L.<italic toggle="yes">,</italic> et al. (2020).</mixed-citation></ref><ref id="bib175"><element-citation publication-type="journal" id="sbref142"><person-group person-group-type="author"><name name-style="western"><surname>Xing</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>O.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name></person-group><article-title>Post-discharge surveillance and positive virus detection in two medical staff recovered from coronavirus disease 2019 (COVID-19), China, January to February 2020</article-title><source>Eur. Surveill.</source><year>2020</year><fpage>25</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2807/1560-7917.ES.2020.25.10.2000191</pub-id><pub-id pub-id-type="pmcid">PMC7078824</pub-id><pub-id pub-id-type="pmid">32183934</pub-id></element-citation></ref><ref id="bib176"><mixed-citation publication-type="other" id="othref0170">Xing, Y., Ni, W., Wu, Q., Li, W., Li, G., Tong, J., Song, X., and Xing, Q. (2020b).</mixed-citation></ref><ref id="bib177"><element-citation publication-type="journal" id="sbref143"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>L.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name></person-group><article-title>High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa</article-title><source>Int J. Oral. Sci.</source><volume>12</volume><year>2020</year><fpage>8</fpage><pub-id pub-id-type="pmid">32094336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41368-020-0074-x</pub-id><pub-id pub-id-type="pmcid">PMC7039956</pub-id></element-citation></ref><ref id="bib178"><element-citation publication-type="journal" id="sbref144"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>P.</given-names></name></person-group><article-title>Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission</article-title><source>Sci. China Life Sci.</source><volume>63</volume><year>2020</year><fpage>457</fpage><lpage>460</lpage><pub-id pub-id-type="pmid">32009228</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11427-020-1637-5</pub-id><pub-id pub-id-type="pmcid">PMC7089049</pub-id></element-citation></ref><ref id="bib179"><element-citation publication-type="journal" id="sbref145"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Pathological findings of COVID-19 associated with acute respiratory distress syndrome</article-title><source>Lancet Respir. Med.</source><volume>8</volume><year>2020</year><fpage>420</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">32085846</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-2600(20)30076-X</pub-id><pub-id pub-id-type="pmcid">PMC7164771</pub-id></element-citation></ref><ref id="bib180"><element-citation publication-type="journal" id="sbref146"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Pathological findings of COVID-19 associated with acute respiratory distress syndrome</article-title><source>Lancet Respir. Med</source><volume>8</volume><year>2020</year><fpage>420</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">32085846</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-2600(20)30076-X</pub-id><pub-id pub-id-type="pmcid">PMC7164771</pub-id></element-citation></ref><ref id="bib181"><element-citation publication-type="journal" id="sbref147"><person-group person-group-type="author"><name name-style="western"><surname>Yamamoto</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ariumi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mizokami</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shimotohno</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yoshikura</surname><given-names>H.</given-names></name></person-group><article-title>Does genetic predisposition contribute to the exacerbation of COVID-19 Symptoms in individuals with comorbidities and explain the huge mortality disparity between the east and the west?</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><fpage>22</fpage><pub-id pub-id-type="pmid">34066804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms22095000</pub-id><pub-id pub-id-type="pmcid">PMC8125927</pub-id></element-citation></ref><ref id="bib182"><element-citation publication-type="journal" id="sbref148"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>F.</given-names></name></person-group><article-title>Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China</article-title><source>J. Infect.</source><volume>80</volume><year>2020</year><fpage>388</fpage><lpage>393</lpage><pub-id pub-id-type="pmid">32112884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jinf.2020.02.016</pub-id><pub-id pub-id-type="pmcid">PMC7102539</pub-id></element-citation></ref><ref id="bib183"><element-citation publication-type="journal" id="sbref149"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Riva</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Martin-Sancho</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kanamune</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sakai</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gotoh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Miorin</surname><given-names>L.</given-names></name><name name-style="western"><surname>De Jesus</surname><given-names>P.D.</given-names></name><etal/></person-group><article-title>MDA5 governs the innate immune response to SARS-CoV-2 in lung epithelial cells</article-title><source>Cell Rep.</source><year>2021</year><fpage>34</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.celrep.2020.108628</pub-id><pub-id pub-id-type="pmcid">PMC7832566</pub-id><pub-id pub-id-type="pmid">33440148</pub-id></element-citation></ref><ref id="bib184"><element-citation publication-type="journal" id="sbref150"><person-group person-group-type="author"><name name-style="western"><surname>Zaim</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Sankaranarayanan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Harky</surname><given-names>A.</given-names></name></person-group><article-title>COVID-19 and multiorgan response</article-title><source>Curr. Probl. Cardiol.</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cpcardiol.2020.100618</pub-id><pub-id pub-id-type="pmcid">PMC7187881</pub-id><pub-id pub-id-type="pmid">32439197</pub-id></element-citation></ref><ref id="bib185"><element-citation publication-type="journal" id="sbref151"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.-j</given-names></name><name name-style="western"><surname>Dong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.-h</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.-d</given-names></name></person-group><article-title>Risk and protective factors for COVID-19 morbidity, severity, and mortality</article-title><source>Clin. Rev. Allergy Immunol.</source><volume>64</volume><year>2022</year><fpage>90</fpage><lpage>107</lpage><pub-id pub-id-type="pmid">35044620</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12016-022-08921-5</pub-id><pub-id pub-id-type="pmcid">PMC8767775</pub-id></element-citation></ref><ref id="bib186"><mixed-citation publication-type="other" id="othref0175">Zhang, D., Guo, R., Lei, L., Liu, H., Wang, Y., Wang, Y., Dai, T., Zhang, T., Lai, Y., Wang, J.<italic toggle="yes">,</italic> et al. (2020).</mixed-citation></ref><ref id="bib187"><element-citation publication-type="journal" id="sbref152"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Su</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019</article-title><source>Clin. Infect. Dis.</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciaa344</pub-id><pub-id pub-id-type="pmcid">PMC7184337</pub-id><pub-id pub-id-type="pmid">32221519</pub-id></element-citation></ref><ref id="bib188"><element-citation publication-type="journal" id="sbref153"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name></person-group><article-title>Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) pneumonia: a multicenter study</article-title><source>AJR Am. J. Roentgenol.</source><volume>214</volume><year>2020</year><fpage>1072</fpage><lpage>1077</lpage><pub-id pub-id-type="pmid">32125873</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2214/AJR.20.22976</pub-id></element-citation></ref><ref id="bib189"><mixed-citation publication-type="other" id="othref0180">Zhao, X., Zhang, B., Li, P., Ma, C., Gu, J., Hou, P., Guo, Z., Wu, H., and Bai, Y. (2020c).</mixed-citation></ref><ref id="bib190"><element-citation publication-type="journal" id="sbref154"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.G.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Si</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.L.</given-names></name><etal/></person-group><article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title><source>Nature</source><volume>579</volume><year>2020</year><fpage>270</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">32015507</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2012-7</pub-id><pub-id pub-id-type="pmcid">PMC7095418</pub-id></element-citation></ref><ref id="bib191"><mixed-citation publication-type="other" id="othref0185">Zhou, Y., Fu, B., Zheng, X., Wang, D., Zhao, C., qi, Y., Sun, R., Tian, Z., Xu, X., and Wei, H. (2020b).</mixed-citation></ref><ref id="bib192"><element-citation publication-type="journal" id="sbref155"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Song</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>R.</given-names></name><etal/></person-group><article-title>A novel coronavirus from patients with pneumonia in China, 2019</article-title><source>N. Engl. J. Med</source><volume>382</volume><year>2020</year><fpage>727</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">31978945</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2001017</pub-id><pub-id pub-id-type="pmcid">PMC7092803</pub-id></element-citation></ref><ref id="bib193"><element-citation publication-type="journal" id="sbref156"><person-group person-group-type="author"><name name-style="western"><surname>Ziegler</surname><given-names>C.G.K.</given-names></name><name name-style="western"><surname>Allon</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Nyquist</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Mbano</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Miao</surname><given-names>V.N.</given-names></name><name name-style="western"><surname>Tzouanas</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yousif</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Bals</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hauser</surname><given-names>B.M.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues</article-title><source>Cell</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.04.035</pub-id><pub-id pub-id-type="pmcid">PMC7252096</pub-id><pub-id pub-id-type="pmid">32413319</pub-id></element-citation></ref></ref-list><sec sec-type="data-availability" id="da0005"><title>Data Availability</title><p id="p0025">No data was used for the research described in the article.</p></sec></back></article></pmc-articleset>